US20190046496A1 - Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality - Google Patents
Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality Download PDFInfo
- Publication number
- US20190046496A1 US20190046496A1 US15/914,141 US201815914141A US2019046496A1 US 20190046496 A1 US20190046496 A1 US 20190046496A1 US 201815914141 A US201815914141 A US 201815914141A US 2019046496 A1 US2019046496 A1 US 2019046496A1
- Authority
- US
- United States
- Prior art keywords
- dronedarone
- patients
- heart failure
- cardiovascular
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 title claims abstract description 143
- 229960002084 dronedarone Drugs 0.000 title claims abstract description 142
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 132
- 230000002265 prevention Effects 0.000 title abstract description 60
- 239000003814 drug Substances 0.000 title abstract description 41
- 238000002360 preparation method Methods 0.000 title abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 118
- 238000000034 method Methods 0.000 claims abstract description 46
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 113
- 206010003662 Atrial flutter Diseases 0.000 claims description 78
- 230000000747 cardiac effect Effects 0.000 claims description 24
- 208000006011 Stroke Diseases 0.000 claims description 22
- 239000002934 diuretic Substances 0.000 claims description 18
- 230000002861 ventricular Effects 0.000 claims description 18
- 206010020772 Hypertension Diseases 0.000 claims description 11
- 229940097420 Diuretic Drugs 0.000 claims description 8
- 230000001882 diuretic effect Effects 0.000 claims description 8
- 239000003286 potassium sparing diuretic agent Substances 0.000 claims description 7
- 229940097241 potassium-sparing diuretic Drugs 0.000 claims description 7
- 208000005189 Embolism Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 230000001746 atrial effect Effects 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 229940122767 Potassium sparing diuretic Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 206010019280 Heart failures Diseases 0.000 description 146
- CPKOXUVSOOKUDA-UHFFFAOYSA-N 1-bromo-5-fluoro-2-iodo-4-methylbenzene Chemical compound CC1=CC(I)=C(Br)C=C1F CPKOXUVSOOKUDA-UHFFFAOYSA-N 0.000 description 76
- 229960002919 dronedarone hydrochloride Drugs 0.000 description 76
- 230000034994 death Effects 0.000 description 70
- 231100000517 death Toxicity 0.000 description 70
- 206010007559 Cardiac failure congestive Diseases 0.000 description 50
- 229940068196 placebo Drugs 0.000 description 43
- 239000000902 placebo Substances 0.000 description 43
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 39
- 239000011591 potassium Substances 0.000 description 39
- 229910052700 potassium Inorganic materials 0.000 description 39
- 230000000004 hemodynamic effect Effects 0.000 description 32
- 230000007423 decrease Effects 0.000 description 28
- 206010042434 Sudden death Diseases 0.000 description 26
- 208000029078 coronary artery disease Diseases 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 22
- 230000009467 reduction Effects 0.000 description 21
- 230000001186 cumulative effect Effects 0.000 description 20
- 230000033764 rhythmic process Effects 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 238000002642 intravenous therapy Methods 0.000 description 17
- 238000000926 separation method Methods 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 208000019622 heart disease Diseases 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 11
- 230000000302 ischemic effect Effects 0.000 description 11
- 208000010125 myocardial infarction Diseases 0.000 description 11
- 229940030606 diuretics Drugs 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 239000003416 antiarrhythmic agent Substances 0.000 description 9
- 230000002085 persistent effect Effects 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000001052 transient effect Effects 0.000 description 8
- 230000002763 arrhythmic effect Effects 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 206010047302 ventricular tachycardia Diseases 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 6
- 230000003288 anthiarrhythmic effect Effects 0.000 description 6
- 238000011863 diuretic therapy Methods 0.000 description 6
- 230000000297 inotrophic effect Effects 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 230000001314 paroxysmal effect Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 206010042772 syncope Diseases 0.000 description 6
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 5
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 206010001497 Agitation Diseases 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 208000010496 Heart Arrest Diseases 0.000 description 4
- 208000019025 Hypokalemia Diseases 0.000 description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
- 208000010378 Pulmonary Embolism Diseases 0.000 description 4
- 208000025747 Rheumatic disease Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 4
- 208000007814 Unstable Angina Diseases 0.000 description 4
- 239000008119 colloidal silica Substances 0.000 description 4
- 208000018578 heart valve disease Diseases 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001992 poloxamer 407 Polymers 0.000 description 4
- 229940044476 poloxamer 407 Drugs 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 230000000552 rheumatic effect Effects 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 208000003663 ventricular fibrillation Diseases 0.000 description 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
- 206010002388 Angina unstable Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000004672 Cardiovascular Infections Diseases 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 3
- 235000019759 Maize starch Nutrition 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000007718 Stable Angina Diseases 0.000 description 3
- 206010042600 Supraventricular arrhythmias Diseases 0.000 description 3
- 208000018452 Torsade de pointes Diseases 0.000 description 3
- 208000002363 Torsades de Pointes Diseases 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000013130 cardiovascular surgery Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000002498 deadly effect Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229960001021 lactose monohydrate Drugs 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 2
- 208000006017 Cardiac Tamponade Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 208000037849 arterial hypertension Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 206010007625 cardiogenic shock Diseases 0.000 description 2
- 238000013153 catheter ablation Methods 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002565 electrocardiography Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 238000013146 percutaneous coronary intervention Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 206010013012 Dilatation ventricular Diseases 0.000 description 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034487 Pericarditis constrictive Diseases 0.000 description 1
- 206010061340 Peripheral embolism Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 206010040639 Sick sinus syndrome Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 201000005180 acute myocarditis Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 206010002895 aortic dissection Diseases 0.000 description 1
- 230000003126 arrythmogenic effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 210000004903 cardiac system Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 208000000839 constrictive pericarditis Diseases 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 1
- 229960002994 dofetilide Drugs 0.000 description 1
- 229940086972 dronedarone 400 mg Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 230000036723 left ventricular dilatation Effects 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000005243 upper chamber Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to the use of dronedarone or pharmaceutically acceptable salts thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization and/or of mortality.
- Dronedarone blocks potassium, sodium and calcium channels and also has anti-adrenergic properties.
- Dronedarone is an anti-arrhythmic that is effective in maintaining sinus rhythm in patients presenting with atrial fibrillation or atrial flutter.
- dronedarone significantly reduces cardiovascular hospitalizations and/or mortality in patients having a history of atrial fibrillation or of atrial flutter, by virtue of its ability to modulate the blood potassium level in a safe and effective way.
- Potassium is the principal intracellular ion and plays an essential role in physiology.
- this ion is the principal osmotically active intracellular ion and plays an important role in the regulation of intracellular volume.
- a constant and stable potassium concentration is essential for the function of enzyme systems and also for good growth and cell division.
- Potassium contributes to establishing the resting potential of the cell membrane and, consequently, changes in potassium concentration, in particular in the extracellular compartment, have effects on cell excitability in the nervous, muscle and cardiac system.
- a decrease in potassium concentration is known to increase cardiac hyperexcitability at the ventricular level, which can result in serious, potentially deadly, rhythm disorders.
- potassium concentration can lead to deadly rhythm disorders; diuretics having a “potassium sparing” effect have demonstrated a beneficial effect in this population.
- Eating habits with a reduced potassium intake may lead to sudden death in predisposed individuals, even without any structural cardiac pathology.
- a complication of the decrease in potassium concentration subsequent to treatment with diuretics may be sudden death, in particular in patients who present an impairment of the contractile function of the heart or left ventricular dysfunction or after a myocardial infarction.
- Regulation of the potassium concentration could therefore play an important beneficial role, in particular in the population of patients who require an anti-arrhythmic treatment (for atrial fibrillation) and who possibly have other risk factors.
- Atrial fibrillation affects about 2.3 million people in North America and 4.5 million people in the European Union and is emerging as a growing public health concern because of the aging of the population.
- AF is a condition in which the upper chambers of the heart beat in an uncoordinated and disorganized fashion, resulting in a very irregular and fast rhythm (i.e., an irregularly, irregular heartbeat).
- blood When blood is not completely pumped out of the heart's chambers, it can pool and clot. If a blood clot forms in the atria, exits the heart and blocks an artery in the brain, a stroke results. Consequently, about 15 percent of strokes result from AF.
- AF is increasingly frequent with advancing age and is often caused by age-related changes in the heart, physical or psychological stress, agents that stimulate the heart, such as caffeine, or as a result of cardiovascular disease. The number is expected to double in the next 20 years. Without appropriate management, AF can lead to serious complications, such as stroke and congestive heart failure.
- Atrial fibrillation itself can cause changes in the electrical parameters of the heart known as electrical remodelling and in the structure of the cardiac chambers known as structural remodelling which tend to decrease the chances of the patient to get back into normal sinus rhythm.
- electrical remodelling changes in the electrical parameters of the heart
- structural remodelling which tend to decrease the chances of the patient to get back into normal sinus rhythm.
- This vicious circle whereby “atrial fibrillation begets atrial fibrillation” has been well documented since the 1990s (Wijffels M C, Kirchhof C J, Dorland R, Allessie M A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995 Oct. 1; 92(7):1954-68.). It explains why when patients have been in atrial fibrillation for a long time they develop permanent atrial fibrillation with little or no chance to recover from this arrhythmia which becomes chronic.
- a subject of the present invention is therefore the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament, wherein said medicament is taken, for use in the prevention of cardiovascular hospitalizations and/or of mortality.
- Said prevention of cardiovascular hospitalizations and/or of mortality is provided to patients having a history of atrial fibrillation or atrial flutter.
- a subject of the present invention is therefore the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalizations and/or of mortality notably in patients having a history of atrial fibrillation or atrial flutter.
- a subject of the present invention is specifically the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalizations and/or of mortality notably in patients having a history of atrial fibrillation or atrial flutter through regulation of the potassium level in the blood.
- cardiovascular mortality Mention may in particular be made of cardiovascular mortality, and more particularly sudden death, also called sudden cardiac death or sudden death from cardiovascular causes.
- a subject of the present invention is also the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament, taken twice a day with a meal, for use in the prevention of mortality and/or of cardiovascular hospitalizations notably in patients having a history of atrial fibrillation or atrial flutter
- a subject of the present invention is the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of approximately 24% of cardiovascular hospitalizations and/or of mortality in patients having a history of atrial fibrillation or atrial flutter, by regulating the potassium level in the blood.
- a subject of the present invention is also the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of approximately 25% of cardiovascular hospitalizations and/or of cardiovascular mortality in patients having a history of atrial fibrillation or atrial flutter, by regulating the potassium level in the blood.
- a subject of the present invention is also the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of approximately 26% of cardiovascular hospitalizations and/or of sudden death in patients having a history of atrial fibrillation or atrial flutter, by regulating the potassium level in the blood.
- a subject of the present invention is also the use of dronedarone or a pharmaceutically acceptable salt thereof, in patients having a history of atrial fibrillation or atrial flutter, for the preparation of a medicament for use in the prevention:
- Another subject of the instant invention is the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of cardiovascular hospitalization and/or of mortality notably in patients with permanent atrial fibrillation or atrial flutter.
- the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for the prevention of about 33% of cardiovascular hospitalization and/or of mortality notably in patients with permanent atrial fibrillation or atrial flutter.
- Another subject of the instant invention is the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of cardiovascular hospitalization and/or of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with structural heart disease particularly structural heart disease in a stable hemodynamic condition.
- the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for the prevention of about 24% of cardiovascular hospitalization and/or of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with structural heart disease in a stable hemodynamic condition.
- the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 24% of cardiovascular hospitalization notably in patients with a history of atrial fibrillation or atrial flutter and with structural heart disease in a stable hemodynamic condition.
- the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 24% of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with structural heart disease in a stable hemodynamic condition.
- the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 33% of cardiovascular mortality notably in patients with a history of atrial fibrillation or atrial flutter and with structural heart disease in a stable hemodynamic condition.
- Said structural heart disease may be coronary heart disease and/or Ischemic dilated cardiomyopathy and/or non-ischemic dilated cardiomyopathy and/or rheumatic valvular heart disease and/or non-rheumatic valvular heart disease and/or hypertrophic cardiomyopathy and/or LVEF ⁇ 45% and/or history of congestive heart failure wherein congestive heart failure may be defined for example as NYHA class III or by a reduced left ventricular ejection fraction below 0.35.
- congestive heart failure is a sub-group of heart failure.
- the subject of the instant invention is also the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of cardiovascular hospitalization and/or of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure in a stable hemodynamic condition.
- the subject of the instant invention is the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of cardiovascular hospitalization and/or of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure defined as NYHA class III in a stable hemodynamic condition.
- the subject of the instant invention is the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of cardiovascular hospitalization and/or of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure defined by a reduced left ventricular ejection fraction below 0.35 in a stable hemodynamic condition.
- the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 44% of cardiovascular hospitalization and/or of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure defined as NYHA class III in a stable hemodynamic condition.
- the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 32% of cardiovascular hospitalization and/or of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure defined by a reduced left ventricular ejection fraction below 0.35 in a stable hemodynamic condition.
- the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure in a stable hemodynamic condition.
- the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 34% of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure defined as NYHA class III in a stable hemodynamic condition.
- the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 45% of death in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure defined with a left ventricular ejection fraction below 0.35 in a stable hemodynamic condition.
- the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of the worsening or development of congestive heart failure notably in patients with a history of atrial fibrillation or atrial flutter.
- the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 22% of the worsening or development of congestive heart failure NYHA class IV in patients with a history of atrial fibrillation or atrial flutter.
- Patients with heart failure in a stable hemodynamic condition may be defined as patients without heart failure in an unstable hemodynamic condition.
- patients with heart failure in an unstable hemodynamic condition may be defined as patients with a severe heart failure and said severe heart failure may be defined by any of the following:
- the invention also relates to the use of dronedarone or pharmaceutically acceptable salts thereof for preparing a medicament for use in the treatment of atrial fibrillation or flutter or for use in the prevention of mortality and/or of cardiovascular hospitalization in patients without severe heart failure.
- a subject of the instant invention also relates to dronedarone or one of its pharmaceutically acceptable salts for the treatment of atrial fibrillation or flutter in patients without severe heart failure, a therapeutic amount of dronedarone or pharmaceutically acceptable salt thereof being administered.
- the invention relates to dronedarone or one of its pharmaceutically acceptable salts for the treatment of atrial fibrillation or flutter in patients without severe heart failure, wherein severe heart failure is indicated by one or more of the following:
- the invention relates to dronedarone or one of its pharmaceutically acceptable salts for the treatment of atrial fibrillation or flutter in patients without severe heart failure, wherein severe heart failure is indicated by hospitalization of the patient for NYHA Class IV heart failure.
- the invention relates to dronedarone or one of its pharmaceutically acceptable salts for the treatment of atrial fibrillation or flutter in patients without severe heart failure, wherein severe heart failure is indicated by hospitalization of the patient for NYHA Class III heart failure within the last month, i.e., one month prior to administration of dronedarone or one of its pharmaceutically acceptable salts.
- Another subject of the invention is performed by providing dronedarone or pharmaceutically acceptable salts thereof, wherein said dronedarone or pharmaceutically acceptable salts thereof is provided along with information indicating that dronedarone or pharmaceutically acceptable salts thereof is indicated in patients with a recent history of or current atrial fibrillation or flutter and without severe heart failure.
- the information indicates that the atrial fibrillation or flutter is non-permanent. In another embodiment, the information indicates that the atrial fibrillation or flutter is associated with at least one risk factor. In another embodiment, the information indicates that severe heart failure is indicated by symptoms of heart failure with minimal exertion within the last month. In another embodiment, the information indicates that severe heart failure is indicated by hospitalization for heart failure within the last month. In another embodiment, the information indicates that severe heart failure is indicated by a history of, or current symptoms of congestive heart failure at rest. In another embodiment, the information indicates that severe heart failure is indicated by hospitalization of the patient for NYHA Class IV heart failure.
- the information indicates that severe heart failure is indicated by hospitalization of the patient for NYHA Class III heart failure within the last month. In another embodiment, the information indicates that severe heart failure is indicated by hospitalization of the patient for heart failure with recent decompensation as indicated by the need for hospitalization or intravenous therapy.
- the information comprises printed matter that advises that dronedarone or pharmaceutically acceptable salts thereof is indicated in patients with either a recent history of or current atrial fibrillation or flutter with associated risk factors and without severe heart failure.
- the printed material is a label.
- providing includes selling, distributing, shipping, offering for sell, importing etc.
- dronedarone for the treatment of may be understood as “use of dronedarone for the preparation of a medicament for use in the treatment of”.
- the treatment of atrial fibrillation or flutter with dronedarone or a pharmaceutically acceptable salt thereof may be contra-indicated for patients with severe heart failure as indicated by any of the following:
- the invention also relates to the use of dronedarone or pharmaceutically acceptable salts thereof for preparing a medicament for use in the treatment of atrial fibrillation or flutter or for use in the prevention of mortality and/or of cardiovascular hospitalizations wherein said medicament is contra-indicated for patients with severe heart failure as indicated by any of the following:
- the invention also relates to a method of promoting the use of dronedarone or pharmaceutically acceptable salts thereof, the method comprising the step of conveying to a recipient at least one message selected from the group consisting of:
- dronedarone or pharmaceutically acceptable salts thereof should be prescribed to a patient who has not been diagnosed with severe heart failure;
- dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with a history of or current symptoms of congestive heart failure;
- dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure;
- dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with symptoms of heart failure with minimal exertion within the last month; and
- dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients who were hospitalized for heart failure within the last month,
- dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients who were hospitalized for NYHA Class IV heart failure,
- dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients who were hospitalized for NYHA Class III heart failure within the last month,
- dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients who were hospitalized for heart failure with recent
- the invention also relates to a method of promoting the use of dronedarone or a pharmaceutically acceptable salt thereof, the method comprising the step of conveying to a recipient at least one message selected from the group consisting of
- the message is provided in a label or package insert.
- the invention also concerns an article of manufacture comprising
- a packaging material b) dronedarone or pharmaceutically acceptable salts thereof, and c) a label or package insert contained within the packaging material indicating that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure.
- the packaging material indicates that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure indicated by one or more of the following:
- the invention also relates to a package comprising dronedarone or pharmaceutically acceptable salts thereof and a label, said label comprising a printed statement which informs a prospective user that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure.
- the printed statement informs a prospective user of one or more of the following:
- dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure indicated by a history of, or current symptoms of congestive heart failure; b) that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure indicated by symptoms of heart failure with minimal exertion within the last month; c) that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure indicated by hospitalization for heart failure within the last month; d) that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure indicated by NHYA Class IV; e) that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure indicated by NYHA Class III within the last month; f) that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure indicated by recent decompensation as indicated by the need for hospitalization or intravenous therapy, for example intravenous inotropic or diuretic therapy; and g) dronedarone or pharmaceutical
- the invention also relates to a package comprising dronedarone or a pharmaceutically acceptable salt thereof and a label, said label comprising at least one message selected from the group consisting of:
- Another method of the invention comprises treating a patient with a recent history of or current atrial fibrillation or flutter, said method comprising administrating to said patient a therapeutically effective amount of dronedarone, or a pharmaceutically acceptable salt thereof, wherein said patient does not have severe heart failure.
- the patient does not have severe heart failure, wherein severe heart failure is indicated by one or more selected from the group consisting of:
- Another method of the invention relates to transforming a patient with a recent history of or current atrial fibrillation or flutter by decreasing the patient's risk of cardiovascular hospitalizations or mortality, comprising administrating to said patient a therapeutically effective amount of dronedarone, or a pharmaceutically acceptable salt thereof, wherein said patient does not have severe heart failure.
- a subject of the invention is a method of decreasing the risk of cardiovascular hospitalizations or mortality in a patient having a history of atrial fibrillation or atrial flutter, said method comprising administering dronedarone, or a pharmaceutically acceptable salt thereof, twice a day with a meal to a patient in need thereof, wherein said patient does not have severe heart failure.
- Diuretics are widely prescribed for their efficacy in the treatment of a diversity of conditions, such as arterial hypertension, congestive heart failure, renal insufficiency, nephrotic syndrome, cirrhosis or glaucoma.
- hypokalaemia is known to increase cardiac excitability, resulting, in certain patients, in ventricular arrhythmia and sudden death (Cooper et al., Circulation, 1999, 100, pages 1311-1315).
- a subject of the present invention is also the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalizations and/or of mortality in patients having a history of atrial fibrillation or atrial flutter and receiving a diuretic-based treatment, in particular a treatment based on non-potassium sparing diuretics.
- a subject of the present invention is also the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood, in particular for use in the prevention of hypokalaemia, especially in patients having histories of atrial fibrillation or atrial flutter and/or patients receiving a diuretic-based treatment, in particular a treatment based on non-potassium sparing diuretics.
- Said diuretic is administered at therapeutically active doses chosen between 1 mg/day and 2 g/day.
- non-potassium sparing diuretic is intended to mean a diuretic which increases potassium excretion.
- cardiovascular hospitalization means a hospitalization which is caused by at least one of the following pathologies (Hohnloser et al., Journal of cardiovascular electrophysiology, January 2008, vol. 19, No. 1, pages 69-73):
- the prevention of cardiovascular hospitalization may be understood as the prevention of cardiovascular hospitalization for at least one of the above mentioned pathologies.
- Mention may be made of the prevention of cardiovascular hospitalization for atrial fibrillation and/or other supraventricular rhythm disorders.
- Mention may also be made of the prevention of cardiovascular hospitalization for transient ischemic event or cerebral stroke.
- a subject of the present invention is also the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the prevention of cardiovascular hospitalization for at least one of the above mentioned pathologies such as atrial fibrillation and/or other supraventricular rhythm disorders and/or stroke.
- cardiovascular mortality covers, in the context of the invention, mortality due to any cardiovascular causes (any death except those due to a non-cardiovascular cause), in particular death from an arrhythmic cause, also called arrhythmic death, and more particularly, sudden death from cardiovascular causes, also called sudden death or sudden cardiac death.
- Cardiovascular mortality may be due for example to:
- den death refers, in general, to death occurring within the hour or less than one hour after the appearance of new symptoms or unexpected death without warning.
- patients having a history of atrial fibrillation or atrial flutter “patients with a history of or a current atrial fibrillation or flutter” or “patients with a recent history of or a current atrial fibrillation or flutter” or “patients with paroxysmal or persistent atrial fibrillation or flutter” or “patients with a history of, or a current paroxysmal or persistent atrial fibrillation or flutter” or “patients with a recent history of, or a current paroxysmal or persistent atrial fibrillation or flutter” or “patients with paroxysmal or intermittent atrial fibrillation or atrial flutter and a recent episode of atrial fibrillation or atrial flutter, who are in sinus rhythm or who will be cardioverted” or “patients with paroxysmal or persistent atrial fibrillation or atrial flutter and a recent episode of atrial fibrillation or atrial flutter, who are in sinus rhythm or who will be cardioverted” or “patients
- this expression means patients with documentation of having been in both atrial fibrillation or flutter and sinus rhythm within the last 6 months preceding the start of treatment. Patients could be either in sinus rhythm, or in atrial fibrillation or flutter at the time the dronedarone or a pharmaceutically acceptable salt thereof is initiated.
- Patients in “permanent atrial fibrillation or flutter” are patients that have all scheduled ECGs in this rhythm throughout the period the dronedarone or a pharmaceutically acceptable salt thereof is administered.
- coronary disease or “coronary heart disease” refers to:
- prevention of cardiovascular hospitalization and/or mortality results in the reduction of the risk of cardiovascular hospitalization and or mortality or in the reduction of the need of cardiovascular hospitalization and or mortality.
- patients notably patients having a history of atrial fibrillation or atrial flutter, mention may also be made of patients also exhibiting at least one of the following risk factors:
- risks factors may be defined as cardiovascular risk factors which are associated to atrial fibrillation.
- the expression “regulating the potassium level in the blood” means preventing the decrease or a possible increase in said level.
- dronedarone and pharmaceutically acceptable salts thereof are generally introduced into pharmaceutical compositions.
- compositions contain an effective dose of dronedarone or of a pharmaceutically acceptable salt thereof, and also at least one pharmaceutically acceptable excipient.
- Said pharmaceutical composition may be given once or twice a day with food.
- the dose of dronedarone administered per day, orally may reach 800 mg, taken in one or more intakes, for example one or two.
- the dose of dronedarone administered may be taken with food.
- the dose of dronedarone administered per day, orally may reach 800 mg, taken in two intakes with a meal.
- the dose of dronedarone administered per day, orally may be taken at a rate of twice a day with a meal for example with the morning and the evening meal.
- the two intakes may comprise same quantity of dronedarone.
- the dosage appropriate for each patient is determined by the physician according to the method of administration, the weight, the pathology, the body surface, the cardiac output and the response of said patient.
- Said excipients are chosen according to the pharmaceutical form and the method of administration desired, from the usual excipients which are known to those skilled in the art.
- compositions for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration dronedarone, or the salt thereof, can be administered in unit administration form, as a mixture with conventional pharmaceutical excipients, to animals and to humans in the cases mentioned above.
- the suitable unit administration forms comprise forms for oral administration, such as tablets, soft or hard gel capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular or intranasal administration forms, forms for administration by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms, and implants.
- oral administration such as tablets, soft or hard gel capsules, powders, granules and oral solutions or suspensions
- sublingual, buccal, intratracheal intraocular or intranasal administration forms, forms for administration by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms, and implants.
- dronedarone and pharmaceutically acceptable salts thereof can be used in creams, gels, ointments or lotions.
- a unit administration form of dronedarone or a pharmaceutically acceptable salt thereof, in tablet form may correspond to one of the following examples:
- Dronedarone hydrochloride (corresponding to 426 65.5 400 mg of base) Methylhydroxypropylcellulose 21.1 3.25 Lactose monohydrate 46.55 7.2 Maize starch 45.5 7 Polyvinylpyrrolidone 65 10 Poloxamer 407 40 6.15 Anhydrous colloidal silica 2.6 0.4 Magnesium stearate 3.25 0.5 650 100
- Dronedarone hydrochloride corresponding to 400 mg 426 65.5 of base
- Microcrystalline cellulose 65
- Anhydrous lactose 42.65 6.6
- Polyvinylpyrrolidone 13 2
- Poloxamer 407 40 6.15 Macrogol 6000 57.5 8.85
- Magnesium stearate 3.25 0.5 650 100
- Dronedarone hydrochloride corresponding to 400 mg of 426 base
- Microcrystalline cellulose 26 Maize starch 45.5
- Poloxamer 407 40
- Dronedarone hydrochloride corresponding to 400 mg of 213 base
- Microcrystalline cellulose 13 Maize starch 22.75
- Poloxamer 407 20
- Anhydrous colloidal silica 1.3 Magnesium stearate 1.625 Lactose monohydrate 20.825 650
- the present invention also relates to a method for treating the pathologies indicated above, which comprises the administration, to a patient, of an effective dose of dronedarone or a pharmaceutically acceptable salt thereof.
- One method of the invention includes decreasing the risk of mortality, cardiac hospitalizations, or the combination thereof in a patient, said method comprising administering to said patient an effective amount of dronedarone or a pharmaceutically acceptable salt thereof, with food.
- the mortality is a cardiovascular mortality. In one embodiment, the mortality is a sudden death.
- Another method of the invention is a method of regulating the potassium level in the blood of a patient having a history of or current atrial fibrillation or atrial flutter, said method comprising administering to said patient dronedarone or a pharmaceutically acceptable salt thereof, with food.
- the patient has a history of or current atrial fibrillation or flutter. In some embodiments of the above methods according to the invention, the patient has a recent history of or a current paroxysmal or persistent atrial fibrillation or atrial flutter. In some embodiments of the above methods according to the invention, the patient has a history of or a current, non permanent atrial fibrillation or atrial flutter. In some embodiments of the above methods according to the invention, the administration of dronedarone or pharmaceutically acceptable salt thereof prevents cardiovascular hospitalizations. In some embodiments of the above methods according to the invention, said patient has a permanent atrial fibrillation or atrial flutter.
- said patient has structural heart disease. In some embodiments of the above methods according to the invention, said patient has congestive heart failure in a stable hemodynamic condition. In some embodiments of the above methods according to the invention, said patient has congestive heart failure defined as NYHA class III in a stable hemodynamic condition. In some embodiments of the above methods according to the invention, said patient has congestive heart failure defined by a reduced left ventricular ejection fraction below 0.35 in a stable hemodynamic condition. In some embodiments of the above methods according to the invention, said patient also exhibits one or more of the above mentioned associated risk factors.
- Another method of the invention is a method of preventing coronary disease in a patient with a history of or current atrial fibrillation or atrial flutter, said method comprising administrating to said patient a therapeutically effective amount of dronedarone or a pharmaceutically acceptable salt thereof.
- said patient further receives a diuretic-based treatment.
- said patient further receives a treatment with a non-potassium-sparing diuretic.
- said patient also exhibits one or more of the above mentioned associated risk factors.
- FIG. 1 represents a Kaplan Meier curve with the cumulative rate of hospitalization or of death from any cause over a period of 30 months;
- FIG. 2 represents a Kaplan Meier curve with the cumulative rate of hospitalization or of cardiovascular death over a period of 30 months;
- FIG. 3 represents a Kaplan Meier curve with the cumulative rate of hospitalization or of sudden death over a period of 30 months;
- FIG. 4 represents a Kaplan Meier curve with the cumulative rate of hospitalization over a period of 30 months
- FIG. 5 represents a Kaplan Meier curve with the cumulative rate of death from any cause over a period of 30 months
- FIG. 6 represents a Kaplan Meier curve with the cumulative rate of cardiovascular death over a period of 30 months
- FIG. 7 represents a Kaplan Meier curve with the cumulative rate of sudden death over a period of 30 months
- FIG. 8 represents the mean variations in potassium between the first and the last administration over a period of 30 months.
- FIG. 9 represents a Kaplan Meier curve with the cumulative rate of hospitalization or of death from any cause over a period of 30 months.
- FIG. 10 represents a Kaplan Meier curve with the cumulative rate of hospitalization or of death from any cause in Patients with NYHA class III congestive heart failure over a period of 30 months.
- the patients had to have a history of atrial fibrillation or flutter and/or could be in normal sinus rhythm or in atrial fibrillation or flutter at inclusion.
- the patient recruitment was carried out by taking into account the following inclusion criteria:
- Pregnant women pregnancy test must be negative
- women or childbearing potential not on adequate birth control only women with a highly effective method of contraception [oral] contraception or intra-uterine device (IUD) or sterile can be randomize.
- oral contraception
- IUD intra-uterine device
- Vaughan Williams Class I and III anti-arrhythmic drugs Need of a concomitant medication that is prohibited in this trial, including the requirement for Vaughan Williams Class I and III anti-arrhythmic drugs, that would preclude the use of study drug during the planned study period, i.e. patients have to stop others antiarrhythmics such as Vaughan Williams Class I and III anti-arrhythmic drugs, for example amiodarone, flecainide, propafenone, quinidine, disopyramide, dofetilide, solatol.
- Vaughan Williams Class I and III anti-arrhythmic drugs for example amiodarone, flecainide, propafenone, quinidine, disopyramide, dofetilide, solatol.
- Plasma potassium ⁇ 3.5 mmol/l as anti-arrhythmic drugs can be arrhythmogenic in patients with hypokalemia, this must be corrected prior to randomization.
- GFR [ml/min] (140 ⁇ AGE [years]*WEIGHT [kilograms]*CONSTANT/CREATININE [ ⁇ mol/L], where CONSTANT is 1 for men and 0.85 for women).
- Treatment was initiated using tablets containing either the placebo or an amount of dronedarone hydrochloride corresponding to 400 mg of dronedarone at a rate of twice a day with the morning and evening meal and more specifically at a rate of one tablet in the morning during or shortly after breakfast and one tablet in the evening during or shortly after dinner.
- the anticipated duration of the treatment was variable according to the time at which each patient was included in the study, and could range from a minimum of 12 months for the last patient included up to a maximum corresponding to the entire duration of the study (12 months+duration of inclusion), i.e. approximately 30 months for the first patients included.
- the relative risk is the ratio of the rates of occurrence of a hospitalization or of a death among the patients on dronedarone, relative to the patients on placebo.
- the percentage reduction x of a given event (hospitalization, death, cardiovascular death, etc.) is calculated in the following way:
- FIG. 1 which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study.
- FIG. 2 which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study.
- FIG. 3 which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study.
- FIG. 4 which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study.
- the calculated relative risk is 0.616, i.e. a reduction in cardiovascular hospitalizations for atrial fibrillation of 38.4%
- FIG. 5 which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study.
- FIG. 6 which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study.
- FIG. 7 which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study.
- the potassium concentration-modulating effect is clearly documented in the study by virtue of the results of analyses of regular blood samples taken throughout the duration of the study in the context of the monitoring of vital parameters.
- Dronedarone therefore makes it possible to regulate the potassium level in the blood.
- the reduction in the risk was greater in the groups of patients liable to be treated with diuretics, such as hypertensive patients, where the reduction in the risk was 62%, against a reduction of 45.5% observed in the patients who were not hypertensive.
- FIG. 9 which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study.
- Calculated relative risk was equal to 0.76, i.e. a decrease of cardiovascular hospitalization or death of 24%.
- Calculated relative risk was equal to 0.56, i.e. a decrease of cardiovascular hospitalization or death of 44%.
- FIG. 10 shows that the effect of dronedarone occurred early and increased over time.
- Calculated relative risk was equal to 0.68, i.e. a decrease of cardiovascular hospitalization or death 32%.
- Calculated relative risk was equal to 0.55, i.e. a decrease of death of 45%.
- Calculated relative risk was equal to 0.855, i.e. a decrease of cardiovascular hospitalization associated with congestive heart failure of 14.5%.
- Calculated relative risk was equal to 0.78, i.e. a decrease of cardiovascular hospitalization associated with class IV congestive heart failure of 22%.
- dronedarone was associated with a 14.5% reduction in the risk of a first cardiovascular hospitalization not due to a supraventricular arrhythmia (HR [95% CI] 0.855 [0.753-0.972]).
- HR [95% CI] 0.855 [0.753-0.972] the lower number of non-AF/AFL hospitalizations on dronedarone was mainly due to fewer hospitalizations for worsening heart failure, MI or unstable angina, or stroke or TIA
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Furan Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.
Description
- The present invention relates to the use of dronedarone or pharmaceutically acceptable salts thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization and/or of mortality.
- 2-n-Butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulphonamidobenzofuran, or dronedarone, and pharmaceutically acceptable salts thereof are described in
European Patent EP 0 471 609 B1. - Dronedarone blocks potassium, sodium and calcium channels and also has anti-adrenergic properties.
- Dronedarone is an anti-arrhythmic that is effective in maintaining sinus rhythm in patients presenting with atrial fibrillation or atrial flutter.
- The applicant has clinically proven that dronedarone significantly reduces cardiovascular hospitalizations and/or mortality in patients having a history of atrial fibrillation or of atrial flutter, by virtue of its ability to modulate the blood potassium level in a safe and effective way.
- In fact, the use of benzofuran derivatives to reduce post-infarction mortality in patients having a reduced left ventricular function after myocardial infarction, without any rhythm disorder requiring an anti-arrhythmic treatment, is known from Patent Applications WO 98/40067 and WO 97/34597.
- However, these applications neither disclose nor suggest the use of dronedarone to reduce cardiovascular hospitalizations and mortality in patients having a history of atrial fibrillation or atrial flutter, in particular by virtue of its ability to modulate the potassium level in the blood.
- Potassium is the principal intracellular ion and plays an essential role in physiology.
- Specifically, this ion is the principal osmotically active intracellular ion and plays an important role in the regulation of intracellular volume.
- A constant and stable potassium concentration is essential for the function of enzyme systems and also for good growth and cell division.
- Potassium contributes to establishing the resting potential of the cell membrane and, consequently, changes in potassium concentration, in particular in the extracellular compartment, have effects on cell excitability in the nervous, muscle and cardiac system.
- A decrease in potassium concentration is known to increase cardiac hyperexcitability at the ventricular level, which can result in serious, potentially deadly, rhythm disorders.
- The deleterious role of a decrease in potassium concentration has been documented in disparate clinical situations.
- For example, in patients suffering from heart failure, the decrease in potassium concentration can lead to deadly rhythm disorders; diuretics having a “potassium sparing” effect have demonstrated a beneficial effect in this population.
- The rapid decrease in potassium concentrations occurring following the abrupt arrest of intense physical exercise could also be responsible for certain sudden deaths.
- A possible contribution of the decrease in potassium concentrations has been mentioned in the sudden death of patients treated with antipsychotics and also in acute alcohol withdrawal syndromes.
- Eating habits with a reduced potassium intake may lead to sudden death in predisposed individuals, even without any structural cardiac pathology.
- The risk of fatal cardiac hyperexcitability is particularly great in patients who receive an anti-arrhythmic treatment which prolongs the duration of cell repolarization, such as sotalol (Sotalex®). These agents may in fact induce a torsade de pointe, which is a severe and potentially deadly ventricular tachycardia. Torsades de pointes are facilitated by the decrease in potassium concentration.
- Finally, it has been shown that the decrease in potassium concentration induces atrial fibrillations (Manoach M., J. Mol. Cell. Cardiol., 1998, 30(6): A4[8]).
- Another clinical situation where the risk of potentially fatal cardiac rhythm disorders is high is represented by patients treated with diuretics, these medicaments, which are widely prescribed in many indications, the most common being arterial hypertension, but also heart failure, renal insufficiency, nephrotic syndrome, cirrhosis and glaucoma, expose the patient to the risk of a decrease in potassium concentration except for “potassium sparing” diuretics.
- A complication of the decrease in potassium concentration subsequent to treatment with diuretics may be sudden death, in particular in patients who present an impairment of the contractile function of the heart or left ventricular dysfunction or after a myocardial infarction.
- Regulation of the potassium concentration could therefore play an important beneficial role, in particular in the population of patients who require an anti-arrhythmic treatment (for atrial fibrillation) and who possibly have other risk factors.
- Now, no anti-arrhythmic, to date, in therapy, has shown effects with regard to the regulation of the potassium level in the blood.
- Atrial fibrillation (AF) affects about 2.3 million people in North America and 4.5 million people in the European Union and is emerging as a growing public health concern because of the aging of the population.
- AF is a condition in which the upper chambers of the heart beat in an uncoordinated and disorganized fashion, resulting in a very irregular and fast rhythm (i.e., an irregularly, irregular heartbeat). When blood is not completely pumped out of the heart's chambers, it can pool and clot. If a blood clot forms in the atria, exits the heart and blocks an artery in the brain, a stroke results. Consequently, about 15 percent of strokes result from AF.
- AF is increasingly frequent with advancing age and is often caused by age-related changes in the heart, physical or psychological stress, agents that stimulate the heart, such as caffeine, or as a result of cardiovascular disease. The number is expected to double in the next 20 years. Without appropriate management, AF can lead to serious complications, such as stroke and congestive heart failure.
- It is known that atrial fibrillation itself can cause changes in the electrical parameters of the heart known as electrical remodelling and in the structure of the cardiac chambers known as structural remodelling which tend to decrease the chances of the patient to get back into normal sinus rhythm. This vicious circle whereby “atrial fibrillation begets atrial fibrillation” has been well documented since the 1990s (Wijffels M C, Kirchhof C J, Dorland R, Allessie M A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995 Oct. 1; 92(7):1954-68.). It explains why when patients have been in atrial fibrillation for a long time they develop permanent atrial fibrillation with little or no chance to recover from this arrhythmia which becomes chronic.
- A subject of the present invention is therefore the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament, wherein said medicament is taken, for use in the prevention of cardiovascular hospitalizations and/or of mortality.
- Said prevention of cardiovascular hospitalizations and/or of mortality is provided to patients having a history of atrial fibrillation or atrial flutter.
- A subject of the present invention is therefore the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalizations and/or of mortality notably in patients having a history of atrial fibrillation or atrial flutter.
- A subject of the present invention is specifically the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalizations and/or of mortality notably in patients having a history of atrial fibrillation or atrial flutter through regulation of the potassium level in the blood.
- Mention may in particular be made of cardiovascular mortality, and more particularly sudden death, also called sudden cardiac death or sudden death from cardiovascular causes.
- A subject of the present invention is also the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament, taken twice a day with a meal, for use in the prevention of mortality and/or of cardiovascular hospitalizations notably in patients having a history of atrial fibrillation or atrial flutter
- More specifically, a subject of the present invention is the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of approximately 24% of cardiovascular hospitalizations and/or of mortality in patients having a history of atrial fibrillation or atrial flutter, by regulating the potassium level in the blood.
- A subject of the present invention is also the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of approximately 25% of cardiovascular hospitalizations and/or of cardiovascular mortality in patients having a history of atrial fibrillation or atrial flutter, by regulating the potassium level in the blood.
- A subject of the present invention is also the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of approximately 26% of cardiovascular hospitalizations and/or of sudden death in patients having a history of atrial fibrillation or atrial flutter, by regulating the potassium level in the blood.
- A subject of the present invention is also the use of dronedarone or a pharmaceutically acceptable salt thereof, in patients having a history of atrial fibrillation or atrial flutter, for the preparation of a medicament for use in the prevention:
-
- of cardiovascular hospitalizations, and more particularly of approximately 25% of cardiovascular hospitalizations, and/or
- of mortality, particularly of approximately 15% of mortality, and more particularly of approximately 16% of mortality, and/or
- of cardiovascular mortality, and more particularly of approximately 30% of cardiovascular mortality, and/or
- of arrhythmic death, and more particularly of approximately 45% of arrhythmic death.
- of sudden death, and more particularly of approximately 59% of sudden death and/or
- Another subject of the instant invention is the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of cardiovascular hospitalization and/or of mortality notably in patients with permanent atrial fibrillation or atrial flutter.
- More precisely, the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for the prevention of about 33% of cardiovascular hospitalization and/or of mortality notably in patients with permanent atrial fibrillation or atrial flutter.
- Another subject of the instant invention is the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of cardiovascular hospitalization and/or of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with structural heart disease particularly structural heart disease in a stable hemodynamic condition.
- More precisely, the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for the prevention of about 24% of cardiovascular hospitalization and/or of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with structural heart disease in a stable hemodynamic condition.
- More precisely, the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 24% of cardiovascular hospitalization notably in patients with a history of atrial fibrillation or atrial flutter and with structural heart disease in a stable hemodynamic condition.
- More precisely, the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 24% of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with structural heart disease in a stable hemodynamic condition.
- More precisely, the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 33% of cardiovascular mortality notably in patients with a history of atrial fibrillation or atrial flutter and with structural heart disease in a stable hemodynamic condition.
- Said structural heart disease may be coronary heart disease and/or Ischemic dilated cardiomyopathy and/or non-ischemic dilated cardiomyopathy and/or rheumatic valvular heart disease and/or non-rheumatic valvular heart disease and/or hypertrophic cardiomyopathy and/or LVEF<45% and/or history of congestive heart failure wherein congestive heart failure may be defined for example as NYHA class III or by a reduced left ventricular ejection fraction below 0.35.
- NYHA means New York Heart Association.
- Mention may be made that congestive heart failure is a sub-group of heart failure.
- Thus, the subject of the instant invention is also the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of cardiovascular hospitalization and/or of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure in a stable hemodynamic condition.
- In an embodiment, the subject of the instant invention is the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of cardiovascular hospitalization and/or of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure defined as NYHA class III in a stable hemodynamic condition.
- In an embodiment, the subject of the instant invention is the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of cardiovascular hospitalization and/or of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure defined by a reduced left ventricular ejection fraction below 0.35 in a stable hemodynamic condition.
- More precisely, the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 44% of cardiovascular hospitalization and/or of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure defined as NYHA class III in a stable hemodynamic condition.
- More precisely, the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 32% of cardiovascular hospitalization and/or of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure defined by a reduced left ventricular ejection fraction below 0.35 in a stable hemodynamic condition.
- In an embodiment, the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure in a stable hemodynamic condition.
- More precisely, the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 34% of mortality notably in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure defined as NYHA class III in a stable hemodynamic condition.
- More precisely, the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 45% of death in patients with a history of atrial fibrillation or atrial flutter and with congestive heart failure defined with a left ventricular ejection fraction below 0.35 in a stable hemodynamic condition.
- In an embodiment, the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of the worsening or development of congestive heart failure notably in patients with a history of atrial fibrillation or atrial flutter.
- More precisely, the invention relates to the use of dronedarone or one of its pharmaceutically acceptable salts for the preparation of a medicament for use in the prevention of about 22% of the worsening or development of congestive heart failure NYHA class IV in patients with a history of atrial fibrillation or atrial flutter.
- Patients with heart failure in a stable hemodynamic condition may be defined as patients without heart failure in an unstable hemodynamic condition.
- In general, patients with heart failure in an unstable hemodynamic condition may be defined as patients with a severe heart failure and said severe heart failure may be defined by any of the following:
-
- worsening symptoms of heart failure at rest or with minimal exertion or,
- history of, or current symptoms of congestive heart failure at rest or,
- symptoms of heart failure with minimal exertion within the last month, i.e. the month prior to start of treatment or,
- hospitalization for heart failure within the last month, i.e. the month prior to start of treatment,
- NYHA Class IV,
- NYHA Class III within the last month,
- recent decompensation as indicated by the need for hospitalization or intravenous therapy, for example intravenous inotropic or diuretic therapy,
- recent decompensation requiring hospitalization or intravenous therapy for the treatment of heart failure.
- Therefore, the invention also relates to the use of dronedarone or pharmaceutically acceptable salts thereof for preparing a medicament for use in the treatment of atrial fibrillation or flutter or for use in the prevention of mortality and/or of cardiovascular hospitalization in patients without severe heart failure.
- A subject of the instant invention also relates to dronedarone or one of its pharmaceutically acceptable salts for the treatment of atrial fibrillation or flutter in patients without severe heart failure, a therapeutic amount of dronedarone or pharmaceutically acceptable salt thereof being administered.
- In one embodiment, the invention relates to dronedarone or one of its pharmaceutically acceptable salts for the treatment of atrial fibrillation or flutter in patients without severe heart failure, wherein severe heart failure is indicated by one or more of the following:
- a) a history of, or current symptoms of congestive heart failure;
b) symptoms of heart failure with minimal exertion within the last month;
c) hospitalization of the patient for heart failure within the last month;
d) hospitalization of the patient for NYHA Class IV heart failure;
e) hospitalization of the patient for NYHA Class III heart failure within the last month,
f) hospitalization of the patient for heart failure with recent decompensation as indicated by the need for hospitalization or intravenous therapy; and
g) hospitalization of the patient for heart failure with recent decompensation requiring hospitalization or intravenous therapy for the treatment of heart failure. - In another embodiment, the invention relates to dronedarone or one of its pharmaceutically acceptable salts for the treatment of atrial fibrillation or flutter in patients without severe heart failure, wherein severe heart failure is indicated by hospitalization of the patient for NYHA Class IV heart failure.
- In another embodiment, the invention relates to dronedarone or one of its pharmaceutically acceptable salts for the treatment of atrial fibrillation or flutter in patients without severe heart failure, wherein severe heart failure is indicated by hospitalization of the patient for NYHA Class III heart failure within the last month, i.e., one month prior to administration of dronedarone or one of its pharmaceutically acceptable salts.
- Another subject of the invention is performed by providing dronedarone or pharmaceutically acceptable salts thereof, wherein said dronedarone or pharmaceutically acceptable salts thereof is provided along with information indicating that dronedarone or pharmaceutically acceptable salts thereof is indicated in patients with a recent history of or current atrial fibrillation or flutter and without severe heart failure.
- In one embodiment, the information indicates that the atrial fibrillation or flutter is non-permanent. In another embodiment, the information indicates that the atrial fibrillation or flutter is associated with at least one risk factor. In another embodiment, the information indicates that severe heart failure is indicated by symptoms of heart failure with minimal exertion within the last month. In another embodiment, the information indicates that severe heart failure is indicated by hospitalization for heart failure within the last month. In another embodiment, the information indicates that severe heart failure is indicated by a history of, or current symptoms of congestive heart failure at rest. In another embodiment, the information indicates that severe heart failure is indicated by hospitalization of the patient for NYHA Class IV heart failure. In another embodiment, the information indicates that severe heart failure is indicated by hospitalization of the patient for NYHA Class III heart failure within the last month. In another embodiment, the information indicates that severe heart failure is indicated by hospitalization of the patient for heart failure with recent decompensation as indicated by the need for hospitalization or intravenous therapy.
- In an embodiment of the invention, the information comprises printed matter that advises that dronedarone or pharmaceutically acceptable salts thereof is indicated in patients with either a recent history of or current atrial fibrillation or flutter with associated risk factors and without severe heart failure. In another embodiment, the printed material is a label.
- The term “providing” includes selling, distributing, shipping, offering for sell, importing etc.
- Mention may be made that “dronedarone for the treatment of” may be understood as “use of dronedarone for the preparation of a medicament for use in the treatment of”.
- The treatment of atrial fibrillation or flutter with dronedarone or a pharmaceutically acceptable salt thereof may be contra-indicated for patients with severe heart failure as indicated by any of the following:
-
- worsening symptoms of heart failure at rest or with minimal exertion or,
- history of, or current symptoms of congestive heart failure at rest or,
- symptoms of heart failure with minimal exertion within the last month, i.e. the month prior to start of treatment or,
- hospitalization for heart failure within the last month, i.e. the month prior to start of treatment,
- NYHA Class IV,
- NYHA Class III within the last month,
- recent decompensation as indicated by the need for hospitalization or intravenous therapy, for example intravenous inotropic or diuretic therapy,
- recent decompensation requiring hospitalization or intravenous therapy for the treatment of heart failure.
- The invention also relates to the use of dronedarone or pharmaceutically acceptable salts thereof for preparing a medicament for use in the treatment of atrial fibrillation or flutter or for use in the prevention of mortality and/or of cardiovascular hospitalizations wherein said medicament is contra-indicated for patients with severe heart failure as indicated by any of the following:
-
- worsening symptoms of heart failure at rest or with minimal exertion or,
- history of, or current symptoms of congestive heart failure at rest or,
- symptoms of heart failure with minimal exertion within the last month, i.e. the month prior to start of treatment or,
- hospitalization for heart failure within the last month, i.e. the month prior to start of treatment,
- NYHA Class IV,
- NYHA Class III within the last month,
- recent decompensation as indicated by the need for hospitalization or intravenous therapy, for example intravenous inotropic or diuretic therapy,
- recent decompensation requiring hospitalization or intravenous therapy for the treatment of heart failure.
- The invention also relates to a method of promoting the use of dronedarone or pharmaceutically acceptable salts thereof, the method comprising the step of conveying to a recipient at least one message selected from the group consisting of:
- (a) dronedarone or pharmaceutically acceptable salts thereof should be prescribed to a patient who has not been diagnosed with severe heart failure;
(b) dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with a history of or current symptoms of congestive heart failure;
(c) dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure;
(d) dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with symptoms of heart failure with minimal exertion within the last month; and
(e) dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients who were hospitalized for heart failure within the last month,
(f) dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients who were hospitalized for NYHA Class IV heart failure,
(g) dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients who were hospitalized for NYHA Class III heart failure within the last month,
(h) dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients who were hospitalized for heart failure with recent decompensation as indicated by the need for hospitalization or intravenous therapy, for example intravenous inotropic or diuretic therapy,
(i) dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients who were hospitalized for heart failure with recent decompensation requiring hospitalization or intravenous therapy for the treatment of heart failure. - The invention also relates to a method of promoting the use of dronedarone or a pharmaceutically acceptable salt thereof, the method comprising the step of conveying to a recipient at least one message selected from the group consisting of
-
- a) a primary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was the time to first hospitalization for cardiovascular reasons or death from any cause;
- b) a secondary endpoint of a study of dronedarone, or pharmaceutically acceptable salt thereof, was death from any cause;
- c) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to death from any cause;
- d) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to cardiovascular death;
- e) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to first hospitalization for cardiovascular reasons;
- f) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to first hospitalization for atrial fibrillation and other supraventricular rhythm disorders;
- g) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to first hospitalization for worsening heart failure;
- h) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to first hospitalization for myocardial infarction;
- i) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to first hospitalization for myocardial infarction;
- j) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to first hospitalization for transient ischemic event or cerebral stroke;
- k) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to sudden death;
- l) dronedarone, or a pharmaceutically acceptable salt thereof, reduced the combined endpoint of cardiovascular hospitalization or death from any cause by about 24 percent;
- m) dronedarone, or a pharmaceutically acceptable salt thereof, reduced the combined endpoint of cardiovascular hospitalization or death from any cause by 24.2 percent;
- n) dronedarone, or a pharmaceutically acceptable salt thereof, reduced the combined endpoint of cardiovascular hospitalization or death from any cause by 24.2 percent, driven by a reduction in cardiovascular hospitalization; and
- o) 70 percent of patients enrolled in a study of dronedarone, or a pharmaceutically acceptable salt thereof, had no heart failure.
- In one embodiment, the message is provided in a label or package insert.
- The invention also concerns an article of manufacture comprising
- a) a packaging material;
b) dronedarone or pharmaceutically acceptable salts thereof, and
c) a label or package insert contained within the packaging material indicating that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure. - In some embodiments, the packaging material indicates that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure indicated by one or more of the following:
- a) a history of, or current symptoms of congestive heart failure;
b) symptoms of heart failure with minimal exertion within the last month;
c) hospitalization of the patient for heart failure within the last month;
d) hospitalization of the patient for NYHA Class IV heart failure;
e) hospitalization of the patient for NYHA Class III heart failure within the last month,
f) hospitalization of the patient for heart failure with recent decompensation as indicated by the need for hospitalization or intravenous therapy; and
g) hospitalization of the patient for heart failure with recent decompensation requiring hospitalization or intravenous therapy for the treatment of heart failure. - The invention also relates to a package comprising dronedarone or pharmaceutically acceptable salts thereof and a label, said label comprising a printed statement which informs a prospective user that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure.
- In some embodiments, the printed statement informs a prospective user of one or more of the following:
- a) that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure indicated by a history of, or current symptoms of congestive heart failure;
b) that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure indicated by symptoms of heart failure with minimal exertion within the last month;
c) that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure indicated by hospitalization for heart failure within the last month;
d) that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure indicated by NHYA Class IV;
e) that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure indicated by NYHA Class III within the last month;
f) that dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients with severe heart failure indicated by recent decompensation as indicated by the need for hospitalization or intravenous therapy, for example intravenous inotropic or diuretic therapy; and
g) dronedarone or pharmaceutically acceptable salts thereof is contraindicated in patients who were hospitalized for heart failure with recent decompensation requiring hospitalization or intravenous therapy for the treatment of heart failure. - The invention also relates to a package comprising dronedarone or a pharmaceutically acceptable salt thereof and a label, said label comprising at least one message selected from the group consisting of:
-
- a) a primary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was the time to first hospitalization for cardiovascular reasons or death from any cause; and
- b) a secondary endpoint of a study of dronedarone, or pharmaceutically acceptable salt thereof, was death from any cause;
- c) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to death from any cause;
- d) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to cardiovascular death;
- e) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to first hospitalization for cardiovascular reasons;
- f) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to first hospitalization for atrial fibrillation and other supraventricular rhythm disorders;
- g) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to first hospitalization for worsening heart failure;
- h) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to first hospitalization for myocardial infarction;
- i) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to first hospitalization for myocardial infarction;
- j) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to first hospitalization for transient ischemic event or cerebral stroke; and
- k) a secondary endpoint of a study of dronedarone, or a pharmaceutically acceptable salt thereof, was time to sudden death,
- l) dronedarone, or a pharmaceutically acceptable salt thereof, reduced the combined endpoint of cardiovascular hospitalization or death from any cause by about 24 percent;
- m) dronedarone, or a pharmaceutically acceptable salt thereof, reduced the combined endpoint of cardiovascular hospitalization or death from any cause by 24.2 percent;
- n) dronedarone, or a pharmaceutically acceptable salt thereof, reduced the combined endpoint of cardiovascular hospitalization or death from any cause by 24.2 percent, driven by a reduction in cardiovascular hospitalization; and
- o) 70 percent of patients enrolled in a study of dronedarone, or a pharmaceutically acceptable salt thereof, had no heart failure.
- Another method of the invention comprises treating a patient with a recent history of or current atrial fibrillation or flutter, said method comprising administrating to said patient a therapeutically effective amount of dronedarone, or a pharmaceutically acceptable salt thereof, wherein said patient does not have severe heart failure.
- In one embodiment, the patient does not have severe heart failure, wherein severe heart failure is indicated by one or more selected from the group consisting of:
-
- a) history of, or current symptoms of congestive heart failure at rest;
- b) symptoms of heart failure with minimal exertion within the last month; and
- c) hospitalization for heart failure within the last month,
- d) NYHA Class IV,
- e) NYHA Class III within the last month,
- f) recent decompensation as indicated by the need for hospitalization or intravenous therapy, for example intravenous inotropic or diuretic therapy,
- g) recent decompensation requiring hospitalization or intravenous therapy for the treatment of heart failure.
- Another method of the invention relates to transforming a patient with a recent history of or current atrial fibrillation or flutter by decreasing the patient's risk of cardiovascular hospitalizations or mortality, comprising administrating to said patient a therapeutically effective amount of dronedarone, or a pharmaceutically acceptable salt thereof, wherein said patient does not have severe heart failure.
- A subject of the invention is a method of decreasing the risk of cardiovascular hospitalizations or mortality in a patient having a history of atrial fibrillation or atrial flutter, said method comprising administering dronedarone, or a pharmaceutically acceptable salt thereof, twice a day with a meal to a patient in need thereof, wherein said patient does not have severe heart failure.
- In terms of clinical study, the prevention of “cardiovascular hospitalizations or of mortality” or of “cardiovascular hospitalizations or of cardiovascular mortality” or of “cardiovascular hospitalizations or of sudden death” constitute what are referred to as composite criteria or a combined endpoint.
- All the percentages given above correspond to average values.
- Diuretics are widely prescribed for their efficacy in the treatment of a diversity of conditions, such as arterial hypertension, congestive heart failure, renal insufficiency, nephrotic syndrome, cirrhosis or glaucoma.
- One of the major consequences of a treatment based on diuretics, except for potassium sparing diuretics, is increased potassium excretion which can result in hypokalaemia.
- Now, hypokalaemia is known to increase cardiac excitability, resulting, in certain patients, in ventricular arrhythmia and sudden death (Cooper et al., Circulation, 1999, 100, pages 1311-1315).
- Advantageously, a subject of the present invention is also the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalizations and/or of mortality in patients having a history of atrial fibrillation or atrial flutter and receiving a diuretic-based treatment, in particular a treatment based on non-potassium sparing diuretics.
- A subject of the present invention is also the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood, in particular for use in the prevention of hypokalaemia, especially in patients having histories of atrial fibrillation or atrial flutter and/or patients receiving a diuretic-based treatment, in particular a treatment based on non-potassium sparing diuretics.
- Said diuretic is administered at therapeutically active doses chosen between 1 mg/day and 2 g/day.
- Among the pharmaceutically acceptable salts of dronedarone, mention may be made of the hydrochloride.
- The term “non-potassium sparing diuretic” is intended to mean a diuretic which increases potassium excretion.
- The term “cardiovascular hospitalization” means a hospitalization which is caused by at least one of the following pathologies (Hohnloser et al., Journal of cardiovascular electrophysiology, January 2008, vol. 19, No. 1, pages 69-73):
-
- relating to atherosclerosis,
- myocardial infarction or unstable angina pectoris,
- stable angina pectoris or atypical thoracic pain,
- syncope,
- transient ischemic event or cerebral stroke (except intracranial haemorrhage),
- atrial fibrillation and other supraventricular rhythm disorders,
- non-fatal cardiac arrest,
- ventricular arrhythmia,
- cardiovascular surgery, except heart transplant,
- heart transplant,
- implantation of a cardiac stimulator (pacemaker), of an implantable defibrillator (“ICD”) or of another cardiac device,
- percutaneous coronary, cerebrovascular or peripheral intervention,
- variations in arterial pressure (hypotension, hypertension, except syncope),
- cardiovascular infection,
- major bleeding/haemorrhage (requiring two or more blood cell pellets or any intracranial haemorrhage),
- pulmonary embolism or deep vein thrombosis,
- worsening of congestive heart failure including acute pulmonary oedema or dyspnoea from cardiac causes.
- Consequently, the prevention of cardiovascular hospitalization may be understood as the prevention of cardiovascular hospitalization for at least one of the above mentioned pathologies.
- Mention may be made of the prevention of cardiovascular hospitalization for atrial fibrillation and/or other supraventricular rhythm disorders.
- Mention may also be made of the prevention of cardiovascular hospitalization for transient ischemic event or cerebral stroke.
- Thus, a subject of the present invention is also the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the prevention of cardiovascular hospitalization for at least one of the above mentioned pathologies such as atrial fibrillation and/or other supraventricular rhythm disorders and/or stroke.
- The term “mortality” or “death” are equivalent and cover mortality due to any cause, whether cardiovascular or non-cardiovascular or unknown.
- The term “cardiovascular mortality” covers, in the context of the invention, mortality due to any cardiovascular causes (any death except those due to a non-cardiovascular cause), in particular death from an arrhythmic cause, also called arrhythmic death, and more particularly, sudden death from cardiovascular causes, also called sudden death or sudden cardiac death.
- Cardiovascular mortality may be due for example to:
-
- Aortic dissection/aneurysm
- Cardiac tamponade
- Cardiogenic shock
- congestive heart failure
- Death during a cardiovascular transcutaneous interventional procedure or cardiovascular surgical intervention
- Hemorrhage (except cardiac tamponade)
- Myocardial infarction or unstable angina (including complications of myocardial infarction, except arrhythmias)
- Pulmonary or peripheral embolism
- Stroke
- Sudden cardiac death (eg, unwitnessed death or documented asystole)
- Ventricular arrhythmia, subclassified as torsades de pointes, ventricular extrasystole, ventricular fibrillation, ventricular tachycardia (non-sustained and sustained ventricular tachycardia), or other ventricular arrhythmia
- Unknown cause
- The term “sudden death” refers, in general, to death occurring within the hour or less than one hour after the appearance of new symptoms or unexpected death without warning.
- It will also be specified that the expression “patients having a history of atrial fibrillation or atrial flutter”, “patients with a history of or a current atrial fibrillation or flutter” or “patients with a recent history of or a current atrial fibrillation or flutter” or “patients with paroxysmal or persistent atrial fibrillation or flutter” or “patients with a history of, or a current paroxysmal or persistent atrial fibrillation or flutter” or “patients with a recent history of, or a current paroxysmal or persistent atrial fibrillation or flutter” or “patients with paroxysmal or intermittent atrial fibrillation or atrial flutter and a recent episode of atrial fibrillation or atrial flutter, who are in sinus rhythm or who will be cardioverted” or “patients with paroxysmal or persistent atrial fibrillation or atrial flutter and a recent episode of atrial fibrillation or atrial flutter, who are in sinus rhythm or who will be cardioverted” means a patient who, in the past, has presented one or more episodes of atrial fibrillation or flutter and/or who is suffering from atrial fibrillation or atrial flutter at the time the dronedarone or a pharmaceutically acceptable salt thereof is used. More particularly, this expression means patients with documentation of having been in both atrial fibrillation or flutter and sinus rhythm within the last 6 months preceding the start of treatment. Patients could be either in sinus rhythm, or in atrial fibrillation or flutter at the time the dronedarone or a pharmaceutically acceptable salt thereof is initiated.
- It will also be specified that the terms “persistent” and “intermittent” are equivalent.
- Patients in “permanent atrial fibrillation or flutter” are patients that have all scheduled ECGs in this rhythm throughout the period the dronedarone or a pharmaceutically acceptable salt thereof is administered.
- The term “coronary disease” or “coronary heart disease” refers to:
-
- 1) Coronary artery disease: documented history of acute myocardial infarction and/or significant (≥70%) coronary artery stenosis and/or history of a revascularization procedure (percutaneous transluminal coronary angioplasty, stent implantation in a coronary artery, coronary artery bypass graft, etc) and/or a positive exercise test and/or positive nuclear scan of cardiac perfusion
- 2) Ischemic dilated cardiomyopathy: clinically significant left ventricular dilatation secondary to coronary artery disease
- Of course, it may be understood that “prevention of cardiovascular hospitalization and/or mortality” results in the reduction of the risk of cardiovascular hospitalization and or mortality or in the reduction of the need of cardiovascular hospitalization and or mortality.
- Among the patients with a recent history of, or a current atrial fibrillation or atrial flutter, mention may be made of patients with a recent history of, or a current, non permanent atrial fibrillation or flutter.
- Among the patients, notably patients having a history of atrial fibrillation or atrial flutter, mention may also be made of patients also exhibiting at least one of the following risk factors:
-
- age notably equal to or above 70, or even above 75,
- hypertension,
- diabetes,
- history of cerebral stroke or of systemic embolism, i.e. prior cerebrovascular accident,
- left atrial diameter greater than or equal to 50 mm measured for example by echocardiography,
- left ventricular ejection fraction less than 40%, measured for example by two-dimensional echography.
- The efficacy of dronedarone to reduce cardiovascular hospitalization or death is now clinically proven in patients with the above mentioned associated risk factors.
- The above mentioned risks factors may be defined as cardiovascular risk factors which are associated to atrial fibrillation.
- Among the patients, notably patients having a history of atrial fibrillation or atrial flutter, mention may also be made of patients also exhibiting additional risk factors, i.e. at least one of the following pathologies:
-
- hypertension,
- underlying structural heart disease,
- tachycardia,
- coronary disease,
- non-rheumatic heart valve disease,
- dilated cardiomyopathy of ischemic origin,
- ablation of atrial fibrillation or flutter, for example catheter ablation or endomyocardial ablation,
- supraventricular tachycardia other than atrial fibrillation or flutter,
- history of heart valve surgery,
- non-ischemic dilated cardiomyopathy,
- hypertrophic cardiomyopathy,
- rheumatic valve disease,
- sustained ventricular tachycardia,
- congenital cardiopathy,
- ablation, for example catheter ablation, for tachycardia other than for atrial fibrillation or flutter,
- ventricular fibrillation,
and/or at least one cardiac device chosen from: - a cardiac stimulator,
- an implantable defibrillator (“ICD”).
- The expression “regulating the potassium level in the blood” means preventing the decrease or a possible increase in said level.
- The principal classes of non-potassium sparing diuretics are:
-
- thiazide diuretics,
- loop diuretics,
- proximal diuretics (osmotics, carbonic anhydrase inhibitors).
- For their therapeutic use, dronedarone and pharmaceutically acceptable salts thereof are generally introduced into pharmaceutical compositions.
- These pharmaceutical compositions contain an effective dose of dronedarone or of a pharmaceutically acceptable salt thereof, and also at least one pharmaceutically acceptable excipient.
- Said pharmaceutical composition may be given once or twice a day with food.
- The dose of dronedarone administered per day, orally, may reach 800 mg, taken in one or more intakes, for example one or two.
- More specifically, the dose of dronedarone administered may be taken with food.
- More specifically, the dose of dronedarone administered per day, orally, may reach 800 mg, taken in two intakes with a meal.
- The dose of dronedarone administered per day, orally may be taken at a rate of twice a day with a meal for example with the morning and the evening meal.
- More specifically, the two intakes may comprise same quantity of dronedarone.
- There may be specific cases where higher or lower dosages are appropriate; such dosages do not depart from the context of the invention. According to the usual practice, the dosage appropriate for each patient is determined by the physician according to the method of administration, the weight, the pathology, the body surface, the cardiac output and the response of said patient.
- Said excipients are chosen according to the pharmaceutical form and the method of administration desired, from the usual excipients which are known to those skilled in the art.
- In said pharmaceutical compositions for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, dronedarone, or the salt thereof, can be administered in unit administration form, as a mixture with conventional pharmaceutical excipients, to animals and to humans in the cases mentioned above.
- The suitable unit administration forms comprise forms for oral administration, such as tablets, soft or hard gel capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular or intranasal administration forms, forms for administration by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms, and implants. For topical application, dronedarone and pharmaceutically acceptable salts thereof can be used in creams, gels, ointments or lotions.
- By way of example, a unit administration form of dronedarone or a pharmaceutically acceptable salt thereof, in tablet form, may correspond to one of the following examples:
-
Ingredients mg % Dronedarone hydrochloride (corresponding to 426 65.5 400 mg of base) Methylhydroxypropylcellulose 21.1 3.25 Lactose monohydrate 46.55 7.2 Maize starch 45.5 7 Polyvinylpyrrolidone 65 10 Poloxamer 407 40 6.15 Anhydrous colloidal silica 2.6 0.4 Magnesium stearate 3.25 0.5 650 100 -
Ingredients mg % Dronedarone hydrochloride (corresponding to 400 mg 426 65.5 of base) Microcrystalline cellulose 65 10 Anhydrous colloidal silica 2.6 0.4 Anhydrous lactose 42.65 6.6 Polyvinylpyrrolidone 13 2 Poloxamer 407 40 6.15 Macrogol 6000 57.5 8.85 Magnesium stearate 3.25 0.5 650 100 -
Ingredients mg Dronedarone hydrochloride (corresponding to 400 mg of 426 base) Microcrystalline cellulose 26 Maize starch 45.5 Polyvinylpyrrolidone 65 Poloxamer 407 40 Anhydrous colloidal silica 3.25 Magnesium stearate 3.25 Lactose monohydrate 41.65 650 -
Ingredients mg Dronedarone hydrochloride (corresponding to 400 mg of 213 base) Microcrystalline cellulose 13 Maize starch 22.75 Polyvinylpyrrolidone 32.5 Poloxamer 407 20 Anhydrous colloidal silica 1.3 Magnesium stearate 1.625 Lactose monohydrate 20.825 650 - According to another of its aspects, the present invention also relates to a method for treating the pathologies indicated above, which comprises the administration, to a patient, of an effective dose of dronedarone or a pharmaceutically acceptable salt thereof.
- One method of the invention includes decreasing the risk of mortality, cardiac hospitalizations, or the combination thereof in a patient, said method comprising administering to said patient an effective amount of dronedarone or a pharmaceutically acceptable salt thereof, with food.
- In one embodiment, the mortality is a cardiovascular mortality. In one embodiment, the mortality is a sudden death.
- Another method of the invention is a method of regulating the potassium level in the blood of a patient having a history of or current atrial fibrillation or atrial flutter, said method comprising administering to said patient dronedarone or a pharmaceutically acceptable salt thereof, with food.
- In some embodiments of the above methods according to the invention, the patient has a history of or current atrial fibrillation or flutter. In some embodiments of the above methods according to the invention, the patient has a recent history of or a current paroxysmal or persistent atrial fibrillation or atrial flutter. In some embodiments of the above methods according to the invention, the patient has a history of or a current, non permanent atrial fibrillation or atrial flutter. In some embodiments of the above methods according to the invention, the administration of dronedarone or pharmaceutically acceptable salt thereof prevents cardiovascular hospitalizations. In some embodiments of the above methods according to the invention, said patient has a permanent atrial fibrillation or atrial flutter. In some embodiments of the above methods according to the invention, said patient has structural heart disease. In some embodiments of the above methods according to the invention, said patient has congestive heart failure in a stable hemodynamic condition. In some embodiments of the above methods according to the invention, said patient has congestive heart failure defined as NYHA class III in a stable hemodynamic condition. In some embodiments of the above methods according to the invention, said patient has congestive heart failure defined by a reduced left ventricular ejection fraction below 0.35 in a stable hemodynamic condition. In some embodiments of the above methods according to the invention, said patient also exhibits one or more of the above mentioned associated risk factors.
- Another method of the invention is a method of preventing coronary disease in a patient with a history of or current atrial fibrillation or atrial flutter, said method comprising administrating to said patient a therapeutically effective amount of dronedarone or a pharmaceutically acceptable salt thereof. In one embodiment, said patient further receives a diuretic-based treatment. In one embodiment, said patient further receives a treatment with a non-potassium-sparing diuretic. In some embodiments, said patient also exhibits one or more of the above mentioned associated risk factors.
- The present invention is illustrated by the data hereinafter with reference to the attached drawings in which:
-
FIG. 1 represents a Kaplan Meier curve with the cumulative rate of hospitalization or of death from any cause over a period of 30 months; -
FIG. 2 represents a Kaplan Meier curve with the cumulative rate of hospitalization or of cardiovascular death over a period of 30 months; -
FIG. 3 represents a Kaplan Meier curve with the cumulative rate of hospitalization or of sudden death over a period of 30 months; -
FIG. 4 represents a Kaplan Meier curve with the cumulative rate of hospitalization over a period of 30 months; -
FIG. 5 represents a Kaplan Meier curve with the cumulative rate of death from any cause over a period of 30 months; -
FIG. 6 represents a Kaplan Meier curve with the cumulative rate of cardiovascular death over a period of 30 months; -
FIG. 7 represents a Kaplan Meier curve with the cumulative rate of sudden death over a period of 30 months; -
FIG. 8 represents the mean variations in potassium between the first and the last administration over a period of 30 months. -
FIG. 9 represents a Kaplan Meier curve with the cumulative rate of hospitalization or of death from any cause over a period of 30 months. -
FIG. 10 represents a Kaplan Meier curve with the cumulative rate of hospitalization or of death from any cause in Patients with NYHA class III congestive heart failure over a period of 30 months. - The efficacy, relative to a placebo, of dronedarone and of pharmaceutically acceptable salts thereof, in the prevention of cardiovascular hospitalizations or of mortality was demonstrated, by means of dronedarone hydrochloride, in a prospective, multinational, multicentre, double-blind clinical study with random distribution in two groups of treatment (group treated with dronedarone hydrochloride and group treated with a placebo) of patients having a history of atrial fibrillation or atrial flutter.
- The patients had to have a history of atrial fibrillation or flutter and/or could be in normal sinus rhythm or in atrial fibrillation or flutter at inclusion.
- The patient recruitment was carried out by taking into account the following inclusion criteria:
- 1) One of the following risk factors had to be present:
-
- age equal to or greater than 70 years,
- hypertension (taking antihypertensives of at least two different classes),
- diabetes,
- history of cerebral stroke (transient ischemic event or completed cerebral stroke) or of systemic embolism,
- left atrial diameter greater than or equal to 50 mm measured by echocardiography,
- left ventricular ejection fraction less than 40%, measured by two-dimensional echography;
or - age equal to or above 70, or even above 75, possibly combined with at least one of the risk factors below:
- hypertension (taking antihypertensives of at least two different classes),
- diabetes,
- history of cerebral stroke (transient ischemic event or completed cerebral stroke) or of systemic embolism,
- left atrial diameter greater than or equal to 50 mm measured by echocardiography,
- left ventricular ejection fraction less than 40%, measured by two-dimensional echography;
- 2) availability of an electrocardiogram carried out during the past 6 months in order to document the presence or the history of atrial fibrillation or flutter;
- 3) availability of an electrocardiogram carried out during the past 6 months in order to document the presence or absence of normal sinus rhythm.
- Refusal or inability to give informed consent to participate in the study.
- Any non cardiovascular illness or disorder that could preclude participation or severely limit survival including cancer with metastasis and organ transplantation requiring immune suppression.
- Pregnant women (pregnancy test must be negative) or women or childbearing potential not on adequate birth control: only women with a highly effective method of contraception [oral] contraception or intra-uterine device (IUD) or sterile can be randomize.
- Breastfeeding women.
- Previous (2 preceding months) or current participation in another trial with an investigational drug (under development) or with an investigational device.
- Previous participation in this trial.
- Patients in permanent atrial fibrillation
- Patients in unstable hemodynamic condition such as acute pulmonary edema within 12 hours prior to start of study medication; cardiogenic shock; treatment with IV pressor agents; patients on respirator; congestive heart failure of stage NYHA IV within the last 4 weeks; uncorrected, hemodynamically significant primary obstructive valvular disease; hemodynamically significant obstructive cardomyopathy; a cardiac operation or revascularization procedure within 4 weeks preceding randomization
- Planned major non-cardiac or cardiac surgery or procedures including surgery for valvular heart disease, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), or on urgent cardiac transplantation list
- Acute myocarditis or constrictive pericarditis
- Bradycardia<50 bpm and/or PR-interval≥0.28 sec on the last 12-lead ECG.
- Significant sinus node disease (documented pause of 3 seconds or more) or 2nd or 3rd degree atrioventricular block (AV-block) unless treated with a pacemaker.
- Need of a concomitant medication that is prohibited in this trial, including the requirement for Vaughan Williams Class I and III anti-arrhythmic drugs, that would preclude the use of study drug during the planned study period, i.e. patients have to stop others antiarrhythmics such as Vaughan Williams Class I and III anti-arrhythmic drugs, for example amiodarone, flecainide, propafenone, quinidine, disopyramide, dofetilide, solatol.
- Plasma potassium<3.5 mmol/l (as anti-arrhythmic drugs can be arrhythmogenic in patients with hypokalemia, this must be corrected prior to randomization.
- A calculated GFR at baseline<10 ml/min using the Cockroft Gault formula (GFR [ml/min]=(140−AGE [years]*WEIGHT [kilograms]*CONSTANT/CREATININE [μmol/L], where CONSTANT is 1 for men and 0.85 for women).
- Furthermore, the concomitant use of grapefruit juice and all potent inhibitors of CYP3A4 such as ketoconazole were prohibited.
- Treatment was initiated using tablets containing either the placebo or an amount of dronedarone hydrochloride corresponding to 400 mg of dronedarone at a rate of twice a day with the morning and evening meal and more specifically at a rate of one tablet in the morning during or shortly after breakfast and one tablet in the evening during or shortly after dinner.
- The anticipated duration of the treatment was variable according to the time at which each patient was included in the study, and could range from a minimum of 12 months for the last patient included up to a maximum corresponding to the entire duration of the study (12 months+duration of inclusion), i.e. approximately 30 months for the first patients included.
- The results obtained in this trial were analysed by the Kaplan Meier method for the figures, and the relative risk (RR) was estimated using Cox's proportional-effect regression model.
- The relative risk (RR) is the ratio of the rates of occurrence of a hospitalization or of a death among the patients on dronedarone, relative to the patients on placebo.
- The percentage reduction x of a given event (hospitalization, death, cardiovascular death, etc.) is calculated in the following way:
-
x=1−relative risk. - Among the 4628 patients included in the study, 2301 were part of the group treated with dronedarone hydrochloride.
- 917 events were recorded in the placebo group, against 734 in the group treated with dronedarone hydrochloride.
- The calculated relative risk is 0.758 with a p=2×10−8, i.e. a reduction in cardiovascular hospitalizations and deaths of 24.2% on dronedarone hydrochloride, the result being highly significant.
-
FIG. 1 , which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study. - Among the 4628 patients included in the study, 2301 were part of the group treated with dronedarone hydrochloride.
- 892 events were recorded in the placebo group, against 701 in the group treated with dronedarone hydrochloride.
- The calculated relative risk is 0.745 with a p=45×10−10, i.e. a reduction in cardiovascular hospitalizations and cardiovascular deaths of 25.5% on dronedarone hydrochloride, the result being highly significant.
-
FIG. 2 , which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study. - Among the 4628 patients included in the study, 2301 were part of the group treated with dronedarone hydrochloride.
- 873 events were recorded in the placebo group, against 684 in the group treated with dronedarone hydrochloride.
- The calculated relative risk is 0.743 with a p=48×10−10, i.e. a reduction in cardiovascular hospitalizations and sudden deaths of 25.5% on dronedarone hydrochloride, the result being highly significant.
-
FIG. 3 , which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study. - Among the 4628 patients included in the study, 2301 were part of the group treated with dronedarone hydrochloride.
- 859 events were recorded in the placebo group, against 675 in the group treated with dronedarone hydrochloride.
- The calculated relative risk is 0.745 with a p=9×10−9, i.e. a reduction in cardiovascular hospitalizations of 25.5% on dronedarone hydrochloride.
-
FIG. 4 , which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study. - Among the 4628 patients included in the study, 2301 were part of the group treated with dronedarone hydrochloride.
- 457 events were recorded in the placebo group, against 296 in the group treated with dronedarone hydrochloride.
- The calculated relative risk is 0.616, i.e. a reduction in cardiovascular hospitalizations for atrial fibrillation of 38.4%
- Among the 4628 patients included in the study, 2301 were part of the group treated with dronedarone hydrochloride.
- 61 events were recorded in the placebo group, against 43 in the group treated with dronedarone hydrochloride.
- The calculated relative risk is 0.66 with a p=0.027, i.e. a reduction in cardiovascular hospitalizations for transient ischemic event or stroke of 34% on dronedarone hydrochloride.
- III.7. Results Relating to Mortality from any Cause
- Among the 4628 patients included in the study, 2301 were part of the group treated with dronedarone hydrochloride.
- 139 deaths were recorded in the placebo group, against 116 in the group treated with dronedarone hydrochloride.
- The calculated relative risk is 0.844 with a p=0.1758, i.e. a reduction of death of 15.6% on dronedarone hydrochloride.
-
FIG. 5 , which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study. - Among the 4628 patients included in the study, 2301 were part of the group treated with dronedarone hydrochloride.
- 94 cardiovascular deaths were recorded in the placebo group, against 65 in the group treated with dronedarone hydrochloride.
- The calculated relative risk is 0.698 with a p=0.0252, i.e. a reduction in cardiovascular mortality of 30.2% on dronedarone hydrochloride.
-
FIG. 6 , which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study. - Among the 4628 patients included in the study, 2301 were part of the group treated with dronedarone hydrochloride.
- 48 arrhythmic deaths (deaths from cardiac arrhythmia) were recorded in the placebo group, against 26 in the group treated with dronedarone hydrochloride.
- The calculated relative risk is 0.55 with a p=0.001, i.e. a reduction of arrhythmic death of 45% on dronedarone hydrochloride.
- Among the 4628 patients included in the study, 2301 were part of the group treated with dronedarone hydrochloride.
- 35 sudden deaths were recorded in the placebo group, against 14 in the group treated with dronedarone hydrochloride.
- The calculated relative risk is 0.405 with a p=0.0031, i.e. a reduction in sudden death of 59.5% on dronedarone hydrochloride.
-
FIG. 7 , which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study. - The potassium concentration-modulating effect is clearly documented in the study by virtue of the results of analyses of regular blood samples taken throughout the duration of the study in the context of the monitoring of vital parameters.
- The variations in potassium (in mmol/l) between the first and the last administration of the medicament of the study are included in
FIG. 8 , in which B signifies basal level, D signifies day and M signifies month. - An analysis of covariance of the change in blood potassium level, taking into account the starting value during the study after the 24th month, shows a significant different in favour of dronedarone compared to the placebo (p<0.0001).
- Dronedarone therefore makes it possible to regulate the potassium level in the blood.
- The clinical results of the study corroborate the hypothesis that modulating potassium decreases the risk of sudden death, in particular in patients exposed to the risk of a decrease in potassium exacerbated by the administration of a diuretic treatment: the reduction in the risk of sudden death by dronedarone, i.e. the prevention of sudden death compared with the placebo, was 70.4% in the patients on diuretics and 34% in the patients not taking diuretics.
- Furthermore, the reduction in the risk was greater in the groups of patients liable to be treated with diuretics, such as hypertensive patients, where the reduction in the risk was 62%, against a reduction of 45.5% observed in the patients who were not hypertensive.
- Among the 4628 patients included in the study, 2301 were part of the group treated with dronedarone hydrochloride.
- 294 patients who developed permanent atrial fibrillation/flutter in the group treated with placebo versus 178 patients in the group treated with dronedarone hydrochloride (p<0.001).
- 74 events were recorded in the placebo group versus 29 in the group treated with dronedarone hydrochloride.
- The calculated relative risk is 0.67 with a p=0.06, i.e. a reduction in cardiovascular hospitalizations and to mortality in patients with permanent atrial fibrillation/flutter of 33% on dronedarone hydrochloride.
-
FIG. 9 , which reproduces the results obtained, shows a clear separation of the two cumulative curves very soon after the beginning of the treatment, this separation persisting over time throughout the duration of the study. - III.14. Results Relating to the Prevention of Cardiovascular Hospitalization or Death in Patients with a Structural Heart Disease
- From the 4628 patients included in the trial, 2301 were part of the group treated with dronedarone hydrochloride.
- 629 events were reported in the placebo group versus 486 in the group treated with dronedarone hydrochloride.
- Calculated relative risk was equal to 0.76, i.e. a decrease of cardiovascular hospitalization or death of 24%.
- III.15. Results Relating to the Prevention of Cardiovascular Hospitalization in Patients with a Structural Heart Disease
- From the 4628 patients included in the trial, 2301 were part of the group treated with dronedarone hydrochloride.
- 583 events were reported in the placebo group versus 452 in the group treated with dronedarone hydrochloride.
- Calculated relative risk was equal to 0.76, i.e. a decrease of cardiovascular hospitalization of 24%.
- III.16. Results Relating to the Prevention of Death in Patients with a Structural Heart Disease
- From the 4628 patients included in the trial, 2301 were part of the group treated with dronedarone hydrochloride.
- 106 events were reported in the placebo group versus 77 in the group treated with dronedarone hydrochloride.
- Calculated relative risk was equal to 0.76, i.e. a decrease of death of 24%.
- III.17. Results Relating to the Prevention of Cardiovascular Death in Patients with a Structural Heart Disease
- From the 4628 patients included in the trial, 2301 were part of the group treated with dronedarone hydrochloride.
- 75 events were reported in the placebo group versus 48 in the group treated with dronedarone hydrochloride.
- Calculated relative risk was equal to 0.67, i.e. a decrease of cardiovascular deaths of 33%.
- III.18. Results Relating to the Prevention of Cardiovascular Hospitalization and Death in Patients with a Congestive Heart Failure Defined as NYHA Class III in a Stable Hemodynamic Condition
- From the 4628 patients included in the trial, 2301 were part of the group treated with dronedarone hydrochloride.
- At randomization, 109 patients with NYHA class III congestive heart failure in a stable hemodynamic condition were part of the placebo group and 91 patients with NYHA class III congestive heart failure in a stable hemodynamic condition were part of the group treated with dronedarone hydrochloride.
- 71 events were reported in the placebo group versus 40 in the group treated with dronedarone hydrochloride.
- Calculated relative risk was equal to 0.56, i.e. a decrease of cardiovascular hospitalization or death of 44%.
-
FIG. 10 shows that the effect of dronedarone occurred early and increased over time. - III.19. Results Relating to the Prevention of Cardiovascular Hospitalization and Death in Patients with Congestive Heart Failure Defined with a Reduced Left Ventricular Ejection Fraction Below 0.35 in a Stable Hemodynamic Condition
- From the 4628 patients included in the trial, 2301 were part of the group treated with dronedarone hydrochloride.
- At randomization, 87 patients with congestive heart failure in a stable hemodynamic condition as defined by a reduced left ventricular ejection fraction below 0.35 were part of the placebo group and 92 patients with congestive heart failure in a stable hemodynamic condition defined with a reduced left ventricular ejection fraction below 0.35 were part of the group treated with dronedarone hydrochloride.
- 47 events were reported in the placebo group versus 39 in the group treated with dronedarone hydrochloride.
- Calculated relative risk was equal to 0.68, i.e. a decrease of cardiovascular hospitalization or death 32%.
- III.20. Results Relating to the Prevention of Death in Patients with Congestive Heart Failure Defined as NYHA Class III
- From the 4628 patients included in the trial, 2301 were part of the group treated with dronedarone hydrochloride.
- At randomization, 109 patients with NYHA class III congestive heart failure in a stable hemodynamic condition were part of the placebo group and 91 patients with NYHA class III congestive heart failure in a stable hemodynamic condition were part of the group treated with dronedarone hydrochloride.
- 21 events were reported in the placebo group versus 12 in the group treated with dronedarone hydrochloride.
- Calculated relative risk was equal to 0.66, i.e. a decrease of death of 34%.
- III.21. Results Relating to the Prevention of Death in Patients with Congestive Heart Failure in a Stable Hemodynamic Condition as Defined by a Reduced Left Ventricular Ejection Fraction Below 0.35
- From the 4628 patients included in the trial, 2301 were part of the group treated with dronedarone hydrochloride.
- At randomization, 87 patients with congestive heart failure in a stable hemodynamic conditions defined by a reduced left ventricular ejection fraction below 0.35 were part of the placebo group and 92 patients with congestive heart failure in a stable hemodynamic condition as defined by a reduced defined with a left ventricular ejection fraction below 0.35 were part of the group treated with dronedarone hydrochloride.
- 16 events were reported in the placebo group versus 10 in the group treated with dronedarone hydrochloride.
- Calculated relative risk was equal to 0.55, i.e. a decrease of death of 45%.
- III.22. Results Relating to the Prevention of Death in Patients with Congestive Heart Failure in a Stable Hemodynamic Condition as Defined as NYHA Class III and by a Reduced Left Ventricular Ejection Fraction Below 0.35
-
Dronedarone 400 mg Placebo BID (N = 23) (N = 24) Number of events, n 19 13 Median survival 254.0 [131.0; 293.0] 487.0 [182.0; NA] [95% CI] (day) Cumulative incidence 0.348 [0.153; 0.542] 0.292 [0.110; 0.474] of events at 6 months [95% CI] Cumulative incidence 0.696 [0.508; 0.884] 0.375 [0.181; 0.569] of events at 1 year [95% CI] Cumulative incidence 0.837 [0.680; 0.993] 0.578 [0.368; 0.788] of events at 2 years [95% CI] Endpoint's composition: Cardiovascular 15 10 hospitalization Death from any cause 4 3 Cardiovascular death 3 2 Non cardiovascular death 1 1 Log-rank test p-value 0.0711 Relative risk [95% CI]a 0.523 [0.256; 1.070]
III.23. Results Relating to the Prevention of Hospitalizations Associated with Congestive Heart Failure, that is for Patients Who Developed Congestive Heart Failure - From the 4628 patients included in the trial, 2301 were part of the group treated with dronedarone hydrochloride.
- 132 events were reported in the placebo group versus 112 in the group treated with dronedarone hydrochloride.
- Calculated relative risk was equal to 0.855, i.e. a decrease of cardiovascular hospitalization associated with congestive heart failure of 14.5%.
- III.24. Results Relating to the Prevention of Hospitalizations Associated with Class IV Congestive Heart Failure, that is for Patients Who Developed Congestive Heart Failure
- From the 4628 patients included in the trial, 2301 were part of the group treated with dronedarone hydrochloride.
- 54 events were reported in the placebo group versus 42 in the group treated with dronedarone hydrochloride.
- Calculated relative risk was equal to 0.78, i.e. a decrease of cardiovascular hospitalization associated with class IV congestive heart failure of 22%.
- III.25. Results Relating to the Prevention of Cardiovascular Hospitalization or Death in Patients with Coronary Heart Disease
- From the 4628 patients included in the trial, 2301 were part of the group treated with dronedarone hydrochloride.
- At randomization, 737 patients with coronary heart disease were part of the placebo group and 668 patients with coronary heart disease were part of the group treated with dronedarone hydrochloride.
- 350 events were reported in the placebo group versus 252 in the group treated with dronedarone hydrochloride.
- Calculated relative risk was equal to 0.733, i.e. a decrease of cardiovascular hospitalization or death of 27% in patients with coronary heart disease (P=0.0002).
- III.26. Results Relating to the Prevention of Cardiovascular Hospitalization for Patients with Coronary Heart Disease
- From the 4628 patients included in the trial, 2301 were part of the group treated with dronedarone hydrochloride.
- At randomization, 737 patients with coronary heart disease were part of the placebo group and 668 patients with coronary heart disease were part of the group treated with dronedarone hydrochloride.
- 321 events were reported in the placebo group versus 233 in the group treated with dronedarone hydrochloride.
- Calculated relative risk was equal to 0.740, i.e. a decrease of cardiovascular hospitalization of 26% for patients with coronary heart disease (P=0.0005).
- III.27. Results Relating to the Prevention of Death for Patients with Coronary Heart Disease
- From the 4628 patients included in the trial, 2301 were part of the group treated with dronedarone hydrochloride.
- At randomization, 737 patients with coronary heart disease were part of the placebo group and 668 patients with coronary heart disease were part of the group treated with dronedarone hydrochloride.
- 66 events were reported in the placebo group versus 39 in the group treated with dronedarone hydrochloride.
- Calculated relative risk was equal to 0.643, i.e. a decrease of death of 36% for patients with coronary heart disease (P=0.0273).
- III.28. Results Relating to the Prevention of Cardiovascular Death for Patients with Coronary Heart Disease
- From the 4628 patients included in the trial, 2301 were part of the group treated with dronedarone hydrochloride.
- At randomization, 737 patients with coronary heart disease were part of the placebo group and 668 patients with coronary heart disease were part of the group treated with dronedarone hydrochloride.
- 47 events were reported in the placebo group versus 26 in the group treated with dronedarone hydrochloride.
- Calculated relative risk was equal to 0.602, i.e. a decrease of cardiovascular death of 40% (P=0.0355).
- III.29. Results Relating to the Prevention of Cardiovascular Hospitalization and Death in Patients with Cardiovascular Risk Factors
-
N HR (95% CI) Age ≥ 75 years 1925 0.75 (0.65, 0.87) Hypertension 3995 0.77 (0.69, 0.85) Diabetes 945 0.75 (0.61, 0.91) Prior cerebrovascular accident 616 0.80 (0.62, 1.02) or systemic embolism Left atrium diameter >= 50 mm 955 0.77 (0.63, 0.94) LVEF < 0.40 338 0.72 (0.51, 1.00) - Consequently, these results show a decrease of respectively 25%, 23%, 25%, 20%, 23%, 28% of cardiovascular hospitalization and death in patients with at least one of each above cardiovascular risk factors.
-
-
Placebo Dronedarone (N = 2327) (N = 2301) HR (95% CI) Any cardiovascular 859 (36.9%) 675 (29.3%) 0.745 [0.673-0.824] hospitalization Atherosclerosis related (if not 8 (0.3%) 11 (0.5%) 1.282 [0.516-3.187] otherwise specified) Myocardial infarction or 61 (2.6%) 48 (2.1%) 0.742 [0.508-1.083] unstable angina Stable angina pectoris or 41 (1.8%) 45 (2.0%) 1.042 [0.682-1.591] atypical chest pain Syncope 24 (1.0%) 21 (0.9%) 0.836 [0.465-1.501] TIA or stroke (except 35 (1.5%) 28 (1.2%) 0.751 [0.457-1.235] intracranial hemorrhage) Atrial fibrillation and other 457 (19.6%) 296 (12.9%) 0.616 [0.532-0.713] supraventricular rhythm disorders Non-fatal cardiac arrest 2 (<0.1%) 3 (0.1%) 1.442 [0.241-8.632] Cardiovascular surgery 23 (1.0%) 21 (0.9%) 0.852 [0.472-1.540] except cardiac transplantation Implantation of a pacemaker, 29 (1.2%) 32 (1.4%) 1.041 [0.630-1.721] ICD or any other cardiac device Transcutaneous coronary, 31 (1.3%) 27 (1.2%) 0.817 [0.488-1.369] cerebrovascular or peripheral procedure Blood pressure related 21 (0.9%) 21 (0.9%) 0.949 [0.518-1.738] (hypotension, hypertension; except syncope) Cardiovascular infection 0 (0%) 4 (0.2%) NA Major bleeding (requiring two 24 (1.0%) 21 (0.9%) 0.816 [0.454-1.466] or more units of blood or any intracranial hemorrhage) Pulmonary embolism or 3 (0.1%) 10 (0.4%) 3.159 [0.869-11.478] deep vein thrombosis Worsening heart failure, 92 (4.0%) 78 (3.4%) 0.805 [0.595-1.089] including pulmonary edema or dyspnea of cardiac origin Ventricular extrasystoles 1 (<0.1%) 1 (<0.1%) 0.973 [0.061-15.560] Ventricular tachycardia (non- 6 (0.3%) 6 (0.3%) 0.952 [0.307-2.951] sustained and sustained) Ventricular fibrillation 1 (<0.1%) 1 (<0.1%) 0.943 [0.059-15.083] Other ventricular arrhythmia 0 (0%) 1 (<0.1%) NA -
-
Placebo Dronedarone (N = 2327) (N = 2301) HR (95% CI) Any non-AF cardiovascular 511 (22.0%) 438 (19.0%) 0.855 [0.753-0.972] hospitalization Atherosclerosis related (if not 10 (0.4%) 11 (0.5%) 1.094 [0.464-2.575] otherwise specified) Myocardial infarction or unstable 71 (3.1%) 52 (2.3%) 0.730 [0.511-1.045] angina Stable angina pectoris or 53 (2.3%) 51 (2.2%) 0.962 [0.655-1.412] atypical chest pain Syncope 28 (1.2%) 23 (1.0%) 0.822 [0.474-1.427] TIA or stroke (except intracranial 43 (1.8%) 32 (1.4%) 0.742 [0.469-1.172] hemorrhage) Non-fatal cardiac arrest 2 (<0.1) 3 (0.1%) 1.504 [0.251-9.000] Cardiovascular surgery except 28 (1.2%) 24 (1.0%) 0.853 [0.495-1.472] cardiac transplantation Implantation of a pacemaker, 56 (2.4%) 46 (2.0%) 0.819 [0.555-1.210] ICD or any other cardiac device Transcutaneous coronary, 40 (1.7%) 31 (1.3%) 0.773 [0.484-1.235] cerebrovascular or peripheral procedure Blood pressure (hypotension, 26 (1.1%) 25 (1.1%) 0.960 [0.554-1.662] hypertension, not syncope) Cardiovascular infection 0 (0%) 4 (0.2%) NA Major bleeding (requiring two or 28 (1.2%) 27 (1.2%) 0.960 [0.566-1.628] more units of blood or any intracranial hemorrhage) Pulmonary embolism or deep 4 (0.2%) 11 (0.5%) 2.713 [0.864-8.521] vein thrombosis Worsening heart failure, 113 (4.9%) 89 (3.9%) 0.787 [0.596-1.039] including pulmonary edema or dyspnea of cardiac origin Ventricular extrasystoles 1 (<0.1) 1 (<0.1) 1.005 [0.063-16.062] Ventricular tachycardia (non- 7 (0.3%) 6 (0.3%) 0.857 [0.288-2.550] sustained and sustained) Ventricular fibrillation 1 (<0.1) 1 (<0.1) 0.997 [0.062-15.940] Other ventricular arrhythmia 0 (0%) 1 (<0.1) NA - For example, dronedarone was associated with a 14.5% reduction in the risk of a first cardiovascular hospitalization not due to a supraventricular arrhythmia (HR [95% CI] 0.855 [0.753-0.972]). As noted below, the lower number of non-AF/AFL hospitalizations on dronedarone was mainly due to fewer hospitalizations for worsening heart failure, MI or unstable angina, or stroke or TIA
Claims (7)
1. A method of decreasing the risk of cardiac hospitalizations in a patient, said method comprising administering to said patient an effective amount of dronedarone or a pharmaceutically acceptable salt thereof, with food.
2. The method according to claim 1 wherein said patient has a history of or current atrial fibrillation or flutter.
3. The method according to claim 1 wherein the administration of dronedarone or pharmaceutically acceptable salt thereof prevents cardiovascular hospitalizations.
4. The method according to claim 1 wherein said patient further receives a diuretic-based treatment.
5. The method according to claim 4 wherein said diuretic is a non-potassium-sparing diuretic.
6. The method according to claim 1 wherein the patient also exhibits at least one risk factor selected from the group consisting of:
an age greater than or equal to 75,
hypertension,
diabetes,
a history of cerebral stroke or of systemic embolism,
left atrial diameter greater than or equal to 50, and
left ventricular ejection fraction less than 40%.
7. The method according to claim 1 wherein the dose of dronedarone administered per day, orally, is less than or equal 800 mg, measured in base form, and taken in one or more intakes.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/914,141 US20190046496A1 (en) | 2008-04-17 | 2018-03-07 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
US17/066,236 US20210267931A1 (en) | 2008-04-17 | 2020-10-08 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
Applications Claiming Priority (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0802127A FR2930148A1 (en) | 2008-04-17 | 2008-04-17 | Use of dronedarone to prepare medicament to prevent mortality and/or cardiovascular hospitalizations in patients having e.g. history of atrial fibrillation/atrial flutter, cerebrovascular accident and non-rheumatic valvular heart disease |
FR0802127 | 2008-04-17 | ||
US4599508P | 2008-04-18 | 2008-04-18 | |
US6025708P | 2008-06-10 | 2008-06-10 | |
FR0803208 | 2008-06-10 | ||
FR0803208 | 2008-06-10 | ||
US15161109P | 2009-02-11 | 2009-02-11 | |
US15162209P | 2009-02-11 | 2009-02-11 | |
EP09290095.0 | 2009-02-11 | ||
EP09290098 | 2009-02-11 | ||
EP09290098.4 | 2009-02-11 | ||
EP09290095 | 2009-02-11 | ||
US15995609P | 2009-03-13 | 2009-03-13 | |
US12/425,125 US8410167B2 (en) | 2008-04-17 | 2009-04-16 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
US13/847,159 US9107900B2 (en) | 2008-04-17 | 2013-03-19 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality |
US14/812,359 US20150328181A1 (en) | 2008-04-17 | 2015-07-29 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
US15/347,333 US20170273936A1 (en) | 2008-04-17 | 2016-11-09 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
US15/914,141 US20190046496A1 (en) | 2008-04-17 | 2018-03-07 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/347,333 Continuation US20170273936A1 (en) | 2008-04-17 | 2016-11-09 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US202016797926A Continuation | 2008-04-17 | 2020-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190046496A1 true US20190046496A1 (en) | 2019-02-14 |
Family
ID=41278622
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/425,125 Active US8410167B2 (en) | 2008-04-17 | 2009-04-16 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
US12/951,471 Abandoned US20110224293A1 (en) | 2008-04-17 | 2010-11-22 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
US12/951,494 Abandoned US20110213027A1 (en) | 2008-04-17 | 2010-11-22 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
US13/847,159 Active US9107900B2 (en) | 2008-04-17 | 2013-03-19 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality |
US14/812,359 Abandoned US20150328181A1 (en) | 2008-04-17 | 2015-07-29 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
US15/347,333 Abandoned US20170273936A1 (en) | 2008-04-17 | 2016-11-09 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
US15/914,141 Abandoned US20190046496A1 (en) | 2008-04-17 | 2018-03-07 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
US17/066,236 Abandoned US20210267931A1 (en) | 2008-04-17 | 2020-10-08 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/425,125 Active US8410167B2 (en) | 2008-04-17 | 2009-04-16 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
US12/951,471 Abandoned US20110224293A1 (en) | 2008-04-17 | 2010-11-22 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
US12/951,494 Abandoned US20110213027A1 (en) | 2008-04-17 | 2010-11-22 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
US13/847,159 Active US9107900B2 (en) | 2008-04-17 | 2013-03-19 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality |
US14/812,359 Abandoned US20150328181A1 (en) | 2008-04-17 | 2015-07-29 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
US15/347,333 Abandoned US20170273936A1 (en) | 2008-04-17 | 2016-11-09 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/066,236 Abandoned US20210267931A1 (en) | 2008-04-17 | 2020-10-08 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
Country Status (21)
Country | Link |
---|---|
US (8) | US8410167B2 (en) |
EP (3) | EP3195862A1 (en) |
JP (1) | JP2011518785A (en) |
KR (1) | KR20100135909A (en) |
CN (1) | CN102065855A (en) |
AR (1) | AR072950A1 (en) |
AU (1) | AU2009252897B2 (en) |
CA (1) | CA2721489A1 (en) |
DO (1) | DOP2010000299A (en) |
EA (1) | EA025017B1 (en) |
IL (1) | IL208752A0 (en) |
MA (1) | MA32354B1 (en) |
MX (1) | MX2010011414A (en) |
MY (1) | MY153608A (en) |
NI (1) | NI201000172A (en) |
NZ (1) | NZ588623A (en) |
PE (1) | PE20091809A1 (en) |
SV (1) | SV2010003700A (en) |
TW (1) | TWI519298B (en) |
WO (1) | WO2009144550A2 (en) |
ZA (1) | ZA201007248B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2930149B1 (en) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | ASSOCIATION OF DRONEDARONE WITH AT LEAST ONE DIURETIC, ITS THERAPEUTIC APPLICATION |
KR20100135909A (en) | 2008-04-17 | 2010-12-27 | 사노피-아벤티스 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
EP2116239A1 (en) * | 2008-04-29 | 2009-11-11 | Sanofi-Aventis | Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment |
FR2959132A1 (en) * | 2010-04-22 | 2011-10-28 | Sanofi Aventis | METHODS FOR RISK EVALUATION AND REDUCTION |
WO2011135581A2 (en) | 2010-04-28 | 2011-11-03 | Cadila Healthcare Limited | Pharmaceutical compositions of dronedarone |
EP2386300A1 (en) * | 2010-05-11 | 2011-11-16 | Sanofi | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter |
EP2387997A1 (en) * | 2010-05-18 | 2011-11-23 | Sanofi | Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients who developed permanent atrial fibrillation throughout the period the dronedarone is administered |
WO2011141888A1 (en) * | 2010-05-13 | 2011-11-17 | Sanofi | Use of dronedarone for the preparation of a medicament for the prevention of cardiovacular hospitalizations or death or cardiovascular events in patients with permanent atrial fibrillation |
EP2387996A1 (en) * | 2010-05-17 | 2011-11-23 | Sanofi | Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation |
WO2012001673A1 (en) * | 2010-06-28 | 2012-01-05 | Mapi Pharma Holdings (Cyprus) Limited | Amorphous form of dronedarone |
US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
EP2431033A1 (en) | 2010-08-10 | 2012-03-21 | Sanofi | Dronedarone for preventing cardiovascular hospitalization or mortality in patients with lone atrial fibrillation |
WO2012020377A1 (en) | 2010-08-11 | 2012-02-16 | Sanofi | Use of dronedarone for the preparation of a medicament for rhythm- and rate-controlling in patients with atrial fibrillation |
US20130116586A1 (en) | 2011-07-07 | 2013-05-09 | Sanofi | Use of dronedarone or a pharmaceutically acceptable salt thereof for the preparation of a drug for the prevention of atrial fibrillation |
WO2013024411A1 (en) | 2011-08-12 | 2013-02-21 | Lupin Limited | Co-milled formulation of dronedarone |
EP3823507A4 (en) | 2018-07-20 | 2022-06-08 | SharkNinja Operating LLC | Robotic cleaner debris removal docking station |
CN114007621A (en) | 2019-03-05 | 2022-02-01 | 因赛特公司 | JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
WO2024073499A2 (en) * | 2022-09-28 | 2024-04-04 | Bluerock Therapeutics Lp | Compositions and methods for treating graft-related arrhythmia |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4868179A (en) * | 1987-04-22 | 1989-09-19 | Cohn Jay N | Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate |
US4831054A (en) | 1988-04-18 | 1989-05-16 | Taro Pharmaceuticals, Ltd. | 2-Alkyl-3-benzoylbenzofurans useful for treating cardiac arrhythmia |
US4988513A (en) | 1990-01-09 | 1991-01-29 | Monsanto Company | Method of treating hypokalemia |
US4986513A (en) * | 1990-05-07 | 1991-01-22 | Harbor Towne Fence, Inc. | Fence connector assembly |
FR2665444B1 (en) | 1990-08-06 | 1992-11-27 | Sanofi Sa | AMINO-BENZOFURAN, BENZOTHIOPHENE OR INDOLE DERIVATIVES, THEIR PREPARATION PROCESS AND THE COMPOSITIONS CONTAINING THEM. |
FR2735365B1 (en) | 1995-06-14 | 1997-09-05 | Sanofi Sa | USE OF AN ANGIOTENSIN II ANTAGONIST AND A BENZOFURANE DERIVATIVE FOR THE PREPARATION OF A MEDICAMENT USEFUL IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS |
FR2746013B1 (en) * | 1996-03-18 | 1998-05-29 | Sanofi Sa | USE OF ANTIARRHYTHMIC COMPOUNDS IN THE PREVENTION OF POST INFARCT MORTALITY |
FR2760364A1 (en) | 1997-03-10 | 1998-09-11 | Sanofi Sa | USE OF ANTIARRHYTHMIC COMPOUNDS FOR REDUCING MORTALITY AFTER MYOCARDIAL INFARCTION |
US6083991A (en) * | 1997-06-04 | 2000-07-04 | University Of Florida Research Foundation, Inc. | Anti-arrhythmic composition and methods of treatment |
FR2764800B1 (en) * | 1997-06-23 | 1999-09-10 | Sanofi Sa | SOLID PHARMACEUTICAL COMPOSITION CONTAINING BENZOFURAN DERIVATIVES |
AU4426499A (en) | 1998-06-08 | 1999-12-30 | Theravance, Inc. | Novel potassium channel drugs and their uses |
US6897305B2 (en) * | 1998-06-08 | 2005-05-24 | Theravance, Inc. | Calcium channel drugs and uses |
CZ20011590A3 (en) | 1998-11-06 | 2003-01-15 | G. D. Searle & Co. | Medicament for treating cardiovascular disorders and composition containing angiotensin converting enzyme inhibitor, aldosterone antagonist, a loop diuretic and digoxin |
US20030113330A1 (en) * | 1999-11-08 | 2003-06-19 | Uhal Bruce D. | Methods for treating pulmonary fibrosis |
US6411840B1 (en) * | 1999-11-16 | 2002-06-25 | Cardiac Intelligence Corporation | Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation |
FR2803846B1 (en) * | 2000-01-17 | 2002-04-05 | Clariant France Sa | 3- (1-HYDROXY-PENTYLIDENE) -5-NITRO-3H-BENZOFURAN-2-ONE, ITS PREPARATION PROCESS AND ITS USE |
GB0020691D0 (en) | 2000-08-22 | 2000-10-11 | Boehringer Ingelheim Pharma | Pharmaceutical combination |
FR2817865B1 (en) * | 2000-12-11 | 2005-02-18 | Sanofi Synthelabo | AMINOALKOXYBENZOYLE DERIVATIVE IN SALT FORM, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF AS SYNTHESIS INTERMEDIATE |
FR2817750B1 (en) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | DRONEDARONE PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION |
FR2817864B1 (en) | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | METHANESULFONAMIDO-BENZOFURANE DERIVATIVE, ITS PREPARATION METHOD AND ITS USE AS A SYNTHESIS INTERMEDIATE |
AU2002231175A1 (en) * | 2000-12-27 | 2002-07-08 | Focal, Inc. | Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart |
IL146389A0 (en) | 2001-11-08 | 2002-07-25 | Isp Finetech Ltd | Process for the preparation of dronedarone |
US6831102B2 (en) * | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
US20030229007A1 (en) * | 2002-05-30 | 2003-12-11 | Roberto Levi | Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia |
DE10237819A1 (en) * | 2002-08-19 | 2004-03-04 | Bayer Ag | 5-Nitrobenzofurane |
US20050004194A1 (en) * | 2003-05-15 | 2005-01-06 | Graves Kurt Chum | Use of organic compounds |
US20060093673A1 (en) * | 2003-06-27 | 2006-05-04 | Coury Arthur J | Controlled release of anti-arrhythmic agents |
CA2532450C (en) * | 2003-07-16 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Chlorthalidone combinations |
WO2005018635A2 (en) | 2003-08-07 | 2005-03-03 | Cardiome Pharma Corp. | Ion channel modulating activity i |
WO2005048979A2 (en) | 2003-10-06 | 2005-06-02 | Torrent Pharmaceuticals Limited | Pharmaceutical composition having casing with multiple micro tablets |
FR2864536B1 (en) | 2003-12-24 | 2006-03-17 | Clariant France Sa | PROCESS FOR THE PREPARATION OF N-ALKYL-2 (HYDROXY-4-BENZOYL) -3 BENZOFURANES AND INTERMEDIATES FOR CARRYING OUT SAID METHOD |
US20050182105A1 (en) * | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7772232B2 (en) * | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
US20080234337A1 (en) | 2004-08-10 | 2008-09-25 | Ono Pharmaceutical Co., Ltd. | Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist |
FR2875409B1 (en) | 2004-09-17 | 2010-05-07 | Sanofi Aventis | PHARMACEUTICAL COMPOSITION COMPRISING A SOLID POLYMERIC MATRIX DISPERSION COMPRISING A CONTINUOUS PHASE OF POLYDEXTROSE AND A CONTINUOUS PHASE OF A POLYMER OTHER THAN POLYDEXTROSE |
WO2007009462A2 (en) | 2005-07-15 | 2007-01-25 | Region Hovedstaden V/Glostrup Hospital | Treatment of migraine and headaches |
DE102005046539A1 (en) | 2005-09-28 | 2007-03-29 | Anker, Stefan, Prof. Dr. | Method of treating cancer- or cachexia patients, using a pacemaker by mitigating the symptoms of shortness of breath, weakness and fatigue; decreasing the weight loss and/or reduction- or removal of muscle loss |
US20070248564A1 (en) * | 2006-04-25 | 2007-10-25 | Roxane Laboratories, Inc. | Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia |
GB0611210D0 (en) | 2006-06-07 | 2006-07-19 | Cambrex Karlskoga Ab | Process |
CN100560067C (en) | 2006-09-29 | 2009-11-18 | 北京德众万全药物技术开发有限公司 | Hydrochloric acid dronedarone medicinal compositions for oral use and preparation method thereof |
CN101153012B (en) | 2006-09-29 | 2010-06-23 | 北京德众万全药物技术开发有限公司 | Novel method of producing dronedarone key intermediate |
ITPD20060380A1 (en) | 2006-10-12 | 2008-04-13 | Univ Padova | USE OF AMIODARONE AND ITS ANALOGUES AS ANTI-VIRAL AGENTS |
FR2914644B1 (en) | 2007-04-06 | 2009-06-05 | Finorga Soc Par Actions Simpli | PROCESS FOR THE PREPARATION OF 2- (N-BUTYL) -3- (4-HYDROXYBENZOYL) -5-NITROBENZOFURAN |
FR2915482B1 (en) | 2007-04-27 | 2009-11-27 | Finorga | PROCESS FOR THE PREPARATION OF 2- (N-BUTYL) -5-NITROBENZOFURANE |
WO2008141189A1 (en) | 2007-05-09 | 2008-11-20 | Elixir Pharmaceuticals, Inc. | Ghrelin modulating compounds and combinations thereof |
US20090076137A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched dronedarone |
GB0719180D0 (en) | 2007-10-02 | 2007-11-14 | Cambrex Karlskoga Ab | New process |
FR2930149B1 (en) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | ASSOCIATION OF DRONEDARONE WITH AT LEAST ONE DIURETIC, ITS THERAPEUTIC APPLICATION |
FR2930148A1 (en) * | 2008-04-17 | 2009-10-23 | Sanofi Aventis Sa | Use of dronedarone to prepare medicament to prevent mortality and/or cardiovascular hospitalizations in patients having e.g. history of atrial fibrillation/atrial flutter, cerebrovascular accident and non-rheumatic valvular heart disease |
KR20100135909A (en) * | 2008-04-17 | 2010-12-27 | 사노피-아벤티스 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
FR2930150B1 (en) * | 2008-06-24 | 2011-01-14 | Sanofi Aventis | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM RATE IN BLOOD |
EP2116239A1 (en) | 2008-04-29 | 2009-11-11 | Sanofi-Aventis | Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment |
EP2133074A1 (en) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation |
EP2133075A1 (en) | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion |
EP2153830A1 (en) | 2008-08-07 | 2010-02-17 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack |
FR2959132A1 (en) * | 2010-04-22 | 2011-10-28 | Sanofi Aventis | METHODS FOR RISK EVALUATION AND REDUCTION |
EP2364703A1 (en) | 2010-03-12 | 2011-09-14 | Sanofi | Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for administration shortly after amiodarone discontinuation |
EP2386300A1 (en) | 2010-05-11 | 2011-11-16 | Sanofi | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter |
US20120005128A1 (en) * | 2010-06-29 | 2012-01-05 | Sanofi | Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation |
US8602215B2 (en) * | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
JP2013544870A (en) | 2010-12-10 | 2013-12-19 | サノフイ | Use of dronedarone for the preparation of drugs used for risk management of liver damage |
EP2469281A1 (en) | 2010-12-24 | 2012-06-27 | Sanofi | Method for managing the risk of liver injury in patients receiving treatment with dronedarone |
-
2009
- 2009-04-16 KR KR1020107025673A patent/KR20100135909A/en not_active Application Discontinuation
- 2009-04-16 PE PE2009000532A patent/PE20091809A1/en not_active Application Discontinuation
- 2009-04-16 EP EP17155797.8A patent/EP3195862A1/en not_active Ceased
- 2009-04-16 JP JP2011504571A patent/JP2011518785A/en active Pending
- 2009-04-16 MX MX2010011414A patent/MX2010011414A/en not_active Application Discontinuation
- 2009-04-16 EP EP20130170242 patent/EP2684564A1/en not_active Ceased
- 2009-04-16 WO PCT/IB2009/005587 patent/WO2009144550A2/en active Application Filing
- 2009-04-16 MY MYPI2010004843A patent/MY153608A/en unknown
- 2009-04-16 AR ARP090101335A patent/AR072950A1/en unknown
- 2009-04-16 EP EP09754178A patent/EP2280701A2/en not_active Ceased
- 2009-04-16 AU AU2009252897A patent/AU2009252897B2/en active Active
- 2009-04-16 EA EA201071204A patent/EA025017B1/en not_active IP Right Cessation
- 2009-04-16 TW TW098112717A patent/TWI519298B/en active
- 2009-04-16 US US12/425,125 patent/US8410167B2/en active Active
- 2009-04-16 CN CN2009801229246A patent/CN102065855A/en active Pending
- 2009-04-16 CA CA2721489A patent/CA2721489A1/en not_active Abandoned
- 2009-04-16 NZ NZ588623A patent/NZ588623A/en unknown
-
2010
- 2010-10-08 DO DO2010000299A patent/DOP2010000299A/en unknown
- 2010-10-11 ZA ZA2010/07248A patent/ZA201007248B/en unknown
- 2010-10-14 NI NI201000172A patent/NI201000172A/en unknown
- 2010-10-14 IL IL208752A patent/IL208752A0/en active IP Right Grant
- 2010-10-14 SV SV2010003700A patent/SV2010003700A/en not_active Application Discontinuation
- 2010-11-03 MA MA33317A patent/MA32354B1/en unknown
- 2010-11-22 US US12/951,471 patent/US20110224293A1/en not_active Abandoned
- 2010-11-22 US US12/951,494 patent/US20110213027A1/en not_active Abandoned
-
2013
- 2013-03-19 US US13/847,159 patent/US9107900B2/en active Active
-
2015
- 2015-07-29 US US14/812,359 patent/US20150328181A1/en not_active Abandoned
-
2016
- 2016-11-09 US US15/347,333 patent/US20170273936A1/en not_active Abandoned
-
2018
- 2018-03-07 US US15/914,141 patent/US20190046496A1/en not_active Abandoned
-
2020
- 2020-10-08 US US17/066,236 patent/US20210267931A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210267931A1 (en) | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality | |
US20110166220A1 (en) | Dronedarone for the prevention of permanent atrial fibrillation | |
US20110124724A1 (en) | Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potasium level in the blood | |
US20110166221A1 (en) | Use of dronedarone for the preparation of a medicament for use in the prevention of cardioversion | |
US20110136899A1 (en) | Combination of dronedarone with at least one diuretic, and therapeutic use thereof | |
EP2386300A1 (en) | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter | |
WO2012020377A1 (en) | Use of dronedarone for the preparation of a medicament for rhythm- and rate-controlling in patients with atrial fibrillation | |
US20130116586A1 (en) | Use of dronedarone or a pharmaceutically acceptable salt thereof for the preparation of a drug for the prevention of atrial fibrillation | |
TW201529068A (en) | Use of DRONEDARONE for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality | |
EP2431033A1 (en) | Dronedarone for preventing cardiovascular hospitalization or mortality in patients with lone atrial fibrillation | |
EP2387997A1 (en) | Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients who developed permanent atrial fibrillation throughout the period the dronedarone is administered |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |